

1

2

3

# **Infant Aphakia Treatment Study (IATS)**

4

5

6

7

8

9

## **Study Protocol**

10

11

## Table of Contents

	<b>Chapter</b>	<b>Page</b>
12		
13		
14	<b>Chapter</b>	
15		
16	1. Background and Summary	3
17		
18	2. Screening and Enrollment of Patients	6
19		
20	3. Treatment Regimens and Adverse Events	12
21		
22	4. Patient Follow-up, Visual Acuity Assessment, and Reoperations	20
23		
24	5. Statistical Considerations	30
25		
26	6. Parenting Stress	37
27		
28	7. Adherence	45
29		
30	8. Certification of Personnel	49
31		

# Chapter 1

## Background and Summary

### 1.1 Objectives

The Infant Aphakia Treatment Study (IATS) is a randomized, controlled multi-center clinical trial with the following objectives:

- To determine whether infants with a unilateral congenital cataract are more likely to develop better vision following cataract extraction surgery if (1) they undergo the primary implantation of an IOL or if (2) they are treated primarily with a contact lens.
- To determine the occurrence of postoperative complications among infants with a unilateral congenital cataract if (1) they undergo the primary implantation of an IOL or if (2) they are treated primarily with a contact lens.
- To determine whether the parents of infants with a unilateral congenital cataract experience less stress if (1) their child is primarily treated with an IOL or if (2) their child is treated primarily with a contact lens.

### 1.2 Rationale of the Study

The IATS is important for the following reasons:

1. Intraocular lenses (IOLs) are now the accepted treatment after cataract extraction in older children and are being used increasingly in younger children and infants. However, little is known about their safety or the most appropriate power to implant in a rapidly growing eye. Before they supplant contact lenses as the preferred means to optically correct aphakic infants, their safety and efficacy for this age group need to be established.
2. Most of the data addressing the issue of how infants should be corrected optically after removing a unilateral congenital cataract is retrospective and uncontrolled. Most series are highly selective and exclude patients who have failed to return for follow-up examinations. Thus, there is much to be learned regarding the precise estimates of success and the factors associated with favorable and unfavorable outcomes.
3. While contact lenses have been the standard means of optically correcting aphakia in infants, they are associated with a number of problems that limit their effectiveness. These problems include corneal complications such as bacterial keratitis, lens loss, difficulty inserting and removing the lenses in a small child, and difficulty fitting the steep corneas of infants. Adherence with contact lens use is a significant factor in the poor visual outcome in many children with unilateral aphakia.

- 76 4. An alternative treatment modality, the implanting of an IOL, has been used by a few  
77 surgeons to correct unilateral aphakia during infancy. These surgeons have reported  
78 better visual outcomes, but more postoperative complications with the use of IOLs  
79 compared to contact lenses.<sup>1-5</sup> It remains to be determined if the increased incidence of  
80 postoperative complications is sufficiently offset by the improved visual outcome.  
81
- 82 5. A recent series reported that children corrected with IOLs have a lower incidence of  
83 cosmetically significant strabismus than children corrected with contact lenses.<sup>6</sup> The  
84 improved ocular alignment of the patients with IOLs has been ascribed to the constancy  
85 of the optical correction they are receiving relative to that received by children corrected  
86 by contact lenses alone. However, these series have largely focused on older children  
87 with acquired cataracts. It is unknown whether this effect will be observed in infants  
88 with congenital cataracts.  
89
- 90 6. Inserting and removing a contact lens from a small child's eye can be very stressful for  
91 parents, particularly if they are unfamiliar with contact lenses. In addition, many parents  
92 do not trust other caregivers to monitor the child's contact lens wear, limiting their  
93 childcare options. An IOL could potentially obviate these problems and thereby reduce  
94 the stress experienced by the parent of an aphakic child.  
95
- 96 7. Regardless of whether the trial determines that one therapeutic approach results in a  
97 better visual outcome than the other, the data collected will still provide valuable  
98 information regarding the relative risks of surgical complications with these two  
99 treatment modalities.

### 100 1.3 Synopsis of Study Protocol

#### 101 **Major eligibility criteria:**

- 102 • Visually significant congenital cataract ( $\geq 3$  mm central opacity) in only one eye
- 103 • Age 28 days to <7 months and at least 41 post-conceptual weeks at the time of  
104 cataract surgery
- 105 • No microcornea (diameter < 9mm), glaucoma, uveitis, retinal and optic nerve  
106 disease, prematurity, anterior persistent fetal vasculature (PFV) causing stretching of  
107 the ciliary processes or posterior PFV, or ocular disease in the fellow eye

108 **Sample size:** 114 patients recruited over 4 years

109

110 **Treatment groups:** Cataract extraction with randomization to one of two treatment regimens  
111 for the aphakia: IOL correction or contact lens correction.

#### 112 **Examination Schedule:**

- 113 • One day, one week, 1 and 3 months following cataract surgery and then every three  
114 months until the end of the study (about 4 years).
- 115 • Visual acuity assessment at 12 months of age measured by a traveling examiner using  
116 Teller Acuity cards.

- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- Exam under anesthesia at 2-4 weeks prior to the visual acuity assessment at 12 months of age.
  - Assessment of parenting stress at 3 months postoperatively and at 15 months of age.
  - 48-hour recall diaries will be done at the 1-month and the visual acuity assessment visits. These will be followed approximately one month later by completion of the mailed, 7-day Eye Care Diary. 48-Hour recall interviews will be conducted over the telephone by DCC staff quarterly starting 3 months after surgery.

126 **Primary Outcome:** *Difference in grating acuity between all eyes having treatment for*  
127 *cataract and all fellow eyes measured by a traveling examiner using Teller Acuity Cards at 12*  
128 *months of age.*

129

130 **Secondary Outcomes:** Visual function in the eye with the cataract, ocular complications,  
131 parenting stress, compliance with patching and optical correction.

132

133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174

## Chapter 2

### Screening and Enrollment of Patients

#### 2.1 Eligibility Assessment

All infants less than 7 months of age with a unilateral cataract are potentially eligible for the study. The eligibility and exclusion criteria are listed below. Some of the criteria are assessed during a clinical exam (Section 2.4.2) and other criteria must be evaluated during an examination under anesthesia (EUA) (Section 2.4.3). Patients who meet the criteria that do not require an EUA will be approached to provide informed consent to undergo an EUA and be randomized to either IOL or Contact Lens treatment if the criteria are met. For all patients less than 7 months of age with a unilateral cataract, an Initial Screening Form will be completed which requests patient initials and date of birth, an indication of whether or not the patient met the assessed entry criteria, and the reasons an eligible patient was not enrolled in the study. A HIPAA waiver will be obtained at each clinical center to collect screening data for patients not enrolled.

#### 2.2 Informed Consent and Enrollment

Written informed consent must be obtained from the parent(s) or legal guardian(s) of the infant before performing any procedures that are not part of the patient's routine care. The study will be discussed with the parent(s) or legal guardian(s) of a child who is eligible for participation in the study based on criteria assessed during the initial outpatient examination when the diagnosis of a cataract is confirmed. Parent(s) or legal guardian(s) will be given the informed consent to read. The investigator will review potential benefits and risks of participation in the study and answer any questions. If the parent/legal guardian expresses any reservation about the study, it is best to allow the parent/guardian time to think about the study before proceeding to randomization. The parent or legal guardian must also be willing to defer cataract surgery until the child is at least 28 days of age. Discussion of the study with family members and with the patient's pediatrician should be encouraged.

After informed consent is obtained, the Office Exam Form, which contains patient information and data from the clinical exam, is completed and the child will be scheduled for an EUA to complete the eligibility assessment. If the criteria assessed during the EUA are met, then the patient will be considered enrolled in the study and will be randomized to either IOL or Contact Lens treatment (Section 2.5). The surgeon will immediately perform surgery according to the assigned treatment. If the patient does not meet criteria, the patient will not be enrolled in the study and the surgeon will perform a cataract extraction with the aphakia treated with a contact lens. All IATS investigators have agreed not to perform primary IOL implantation in patients less than 7 months of age with a unilateral cataract outside the study. Whether or not the patient is enrolled, the EUA/Surgery Form is completed which records the results of the surgical procedure.

175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217

## **2.3 Eligibility Criteria**

Patients of all races and both genders and independent of socio-economic status will be eligible for the IATS if all of the following findings and conditions are met:

- 1) Age between 28 and 210 days and at least 41 post-conceptual weeks at the time of cataract surgery.
- 2) A visually significant cataract ( $\geq 3$  mm central opacity) in only one eye.
- 3) Informed consent signed by a parent or legal guardian.
- 4) Parent or legal guardian agrees to be contacted by the DCC staff to collect compliance data.

### **2.3.1 Exclusion Criteria**

Patients will be excluded from the IATS if they meet any one of the following criteria:

- 1) The cataract is known to be acquired from trauma or as a side effect of a treatment administered postnatally such as radiation or medical therapy.
- 2) A corneal diameter less than 9 mm measured in the horizontal meridian using calipers.
- 3) An intraocular pressure of 25 mm Hg or greater in the affected eye measured with a Perkins tonometer, tonopen, or pneumotonometer.
- 4) Anterior persistent fetal vasculature (PFV) causing stretching of the ciliary processes or a tractional detachment of the retina.
- 5) Active uveitis or signs suggestive of a previous episode of uveitis such as posterior synechiae or keratic precipitates.
- 6) The child is the product of a pre-term pregnancy ( $<36$  gestational weeks).
- 7) Retinal disease that may limit the visual potential of the eye such as retinopathy of prematurity.
- 8) Previous intraocular surgery.
- 9) Optic nerve disease that may limit the visual potential of the eye.
- 10) The fellow eye has ocular disease that might reduce its visual potential.
- 11) The child has a medical condition known to limit the ability to obtain visual acuity at 12 months or 4 years of age.
- 12) Refusal by the parent or legal guardian to sign an informed consent or to be randomized to one of the two treatment groups.
- 13) Follow-up of the child is not feasible because the child would not be able to return for regular follow-up examinations and the outcome assessments (e.g. transportation difficulties, relocation, etc.).

## **2.4 Examination Procedures**

### **2.4.1 Patient Information**

218 Patient information to be obtained will include: initials, date of birth, birth hospital, gender,  
219 ethnicity, date cataract diagnosed, other congenital abnormalities, referral source, and medical  
220 insurance status.

221

#### 222 **2.4.2 Clinical Testing in Office**

223

224 Examination procedures include:

225

226 1. Ocular motility examination: assess ocular alignment of the eye with the cataract with the  
227 Hirschberg, Krimsky or Alternate Prism and Cover Test at near.

228 2. Presence or absence of nystagmus in the primary position.

229 3. The direct and consensual pupillary light responses.

230 4. Pupil diameter of both eyes.

231

232 Other procedures which are not requested on the Office Exam Form but which are encouraged  
233 include the following:

234

235 1. Visual acuity determined by occluding each eye and assessing the child's visual behavior with  
236 the other eye.

237 2. Slit-lamp examination, if possible. If not possible, assess the red reflex with a direct  
238 ophthalmoscope before and after dilation.

239 3. Examination of the retina and optic nerve using indirect ophthalmoscopy of the unaffected and  
240 affected eye, if possible.

241 4. B-scan ultrasonography of the affected eye if the retina and optic nerve cannot be visualized  
242 with indirect ophthalmoscopy.

243

#### 244 **2.4.3 Clinical Testing Under General Anesthesia**

245

246 After obtaining informed consent from the parent or legal guardian, both eyes are examined  
247 under anesthesia for the eligibility and exclusion criteria prior to cataract surgery . The following  
248 procedures are performed during this examination:

249

250 Thirty (30) minutes prior to the examination-under-anesthesia, both the affected and unaffected  
251 eyes should be dilated with one drop of 1% cyclopentolate and one drop of 2.5% neosynephrine.

252 The drops may be repeated on two occasions, every 5 minutes.

253

254 The following studies are to be performed during the examination-under-anesthesia.

255

256 1. Tonometry, immediately after induction of general anesthesia, using a pneumotonometer,  
257 tonopen or Perkins tonometer.

258 2. Measurement of the horizontal corneal diameter using calipers.

259 3. Biomicroscopy using a hand-held slit lamp.

260 4. Keratometry of both eyes - Ideally a handheld autokeratometer should be used to obtain the  
261 K readings such as the Alcon Renaissance Hand Held Keratometer, but if this is unavailable a

262 manual keratometer may be used. At least two keratometry measurements should be taken in



263 both the affected and unaffected eyes to ensure that the results are accurate; the 2 average K  
264 readings should be within 1 D of each other. If the two average K readings are more than 1 D  
265 different, then make a third measurement and find the average of the two closest K readings.  
266 5. Cycloplegic refraction using retinoscopy of the fellow eye and of the eye with the cataract  
267 6. Examination of the retina and optic nerve using indirect ophthalmoscopy.  
268 7. B-scan ultrasonography if the retina and optic nerve cannot be visualized with indirect  
269 ophthalmoscopy.  
270 8. A-scan biometry of both eyes using immersion if possible – take the measurement from the  
271 scan with the best wave forms (i.e., highest peaks with a perpendicular retinal spike) or, if  
272 applanation biometry is used, the A-scan with the greatest AC depth. The phakic setting on the  
273 ultrasound unit should be used when obtaining the axial length measurements. The axial length  
274 measurement from the affected eye with the deepest anterior chamber depth and a 90 degree  
275 angle between the baseline and the retinal spike should be used for the IOL calculations.  
276

## 277 **2.5 Specifics of the Patient Randomization Process**

278

279 For patients who meet the eligibility criteria of the first stage of screening and the parents agree  
280 to participate in the study or the decision is pending, the clinical coordinator faxes the Initial  
281 Screening Form to the DCC and calls the DCC alerting them that the fax has been sent. DCC  
282 staff will fax to the clinical center a Treatment Assignment Envelope Form with the patient's  
283 IATS ID, initials, date of birth, scheduled surgery date, patient's age at surgery and the color and  
284 letter code of the treatment assignment envelope to use for this patient.  
285

286 Before the study starts, each center will be given a batch of 52 treatment assignment envelopes.  
287 There will be two sets of 26 envelopes each, one set for each of the two age strata (28-48 days  
288 old at surgery and 49-210 days old at surgery). The envelopes for the two age strata will have  
289 different colors. Each envelope will have a unique code consisting of two letters. One letter  
290 indicates the age stratum with 'Y' for the 28-48 days old stratum and 'O' for the 49-210 days old  
291 stratum. For each stratum the second letter will identify the specific envelope and will consist of  
292 the letters A-Z. Thus, the 28-48 days old stratum envelopes will have letter codes 'YA' – 'YZ'  
293 and the 49-210 days old stratum envelopes will have letter codes 'OA' – 'OZ'. **NOTE: The**  
294 **envelopes will not be used in order according to the code on the envelope. For each patient**  
295 **you will receive a Treatment Assignment Envelope Form from the DCC specifying the**  
296 **letter code for the envelope to use.** For example, if your first patient is 95 days old at surgery,  
297 the envelope you might be told to use could be "OP".  
298

299 If surgery is delayed beyond the originally scheduled date, the treatment assignment envelope  
300 may no longer be valid. This would happen, for example, if a patient would have been 48 days  
301 old or less at the time of the originally schedule surgery but because the surgery is delayed the  
302 patient will be older than 48 days at the new surgery date. In this case, the patient would move  
303 from the younger age stratum to the older age stratum and the treatment assignment envelope  
304 would have to be changed. If this happens, the clinical coordinator will mail the original  
305 treatment assignment envelope back to the DCC. Also, the clinical coordinator should modify  
306 the Initial Screening Form to indicate the new surgery date and then re-fax the form to the DCC.  
307 The DCC will fax a new Treatment Assignment Envelope Form specifying the code for the

308 treatment assignment envelope to be used for the patient. The Treatment Assignment Envelope  
309 Form will also indicate the last date on which surgery could be done for the patient to not exceed  
310 the maximum age limit for the study.

311  
312 At the time of surgery, the clinical coordinator retrieves the treatment assignment envelope with  
313 the code indicated on the Treatment Assignment Envelope Form. The treatment assignment  
314 envelope will be taken to the EUA along with the IOL Power Table and the yellow instruction  
315 sheet listing the EUA and surgical protocol procedures. The treatment assignment envelope will  
316 remain sealed until the surgeon has confirmed that the patient is eligible for the study. If the  
317 patient meets all the eligibility requirements, the patient is officially enrolled and the treatment  
318 assignment envelope can be opened. A card with a peel-off label containing the treatment  
319 assignment is removed and the label is placed in the space provided on the EUA/Surgery form.  
320 The label will also contain the ID of the treatment assignment envelope. The surgeon then  
321 performs the assigned treatment. If the surgeon determines that the patient does not qualify for  
322 the study, the treatment assignment envelope remains sealed and the envelope is mailed to the  
323 DCC. The surgeon will perform a cataract extraction and the aphakia will be treated with a  
324 contact lens.

325  
326 After the EUA and surgery, whether or not the patient qualifies for the study, the clinical  
327 coordinator and surgeon complete the EUA/Surgery Form, which the clinical coordinator faxes  
328 to the DCC along with the A-scan tracing from which the axial length was determined.

329

## 330 **2.6 Case Report Forms (CRFs)**

331

332 In this study, data will be collected by having clinical center personnel complete paper CRFs that  
333 are faxed to the DCC.

334

335 Each center will have a Screening Binder containing:

336 1) Screening Log – A log to track all patients screened at the center.

337 2) Numbered Patient Screening Forms Sections – ID numbered sections containing:

338 A) Initial Screening Form – Blank copies of the Initial Screening Form

339 B) Office Exam Form – Blank copies of the Office Exam Form

340 C) EUA/Surgery Form – Blank copies of the EUA/Surgery Form.

341

342 If a patient with a unilateral cataract is screened and found to be ineligible before the EUA, then  
343 only the Initial Screening Form is completed and this form is stored in the Screening Binder.

344 If the patient is found to be ineligible at the EUA, the forms listed under A-C above are stored in  
345 the Screening Binder. If the patient was randomized, the Initial Screening Form, Informed  
346 Consent Form, Office Examination Form, Treatment Assignment Envelope Form and  
347 EUA/Surgery Form are moved to a Patient CRF Binder, which has blank copies of the remaining  
348 CRFs needed to record the patient's data. Each enrolled patient will have a separate Patient CRF  
349 Binder.

350

351  
352 The CRFs should be completely filled out, in English, with blue or black ink, on the day of the  
353 visit, signed by the PI, faxed to the DCC, and kept in the appropriate section of the Patient CRF  
354 Binder. The information recorded on the CRF should accurately reflect the findings of the study  
355 visit as recorded in the patient's medical record. Any errors made in recording data on the CRF  
356 should be corrected by

- 357       1) drawing a line through the error,  
358       2) writing the correct value next to it, and  
359       3) initialing and dating the correction.

360 The erroneous value should never be obscured by heavy ink, permanent marker, or white-out.  
361

## 362 **2.7 Patient Contact Information**

363  
364 Adherence with patching and wearing optical correction is an important determinant of success  
365 for either treatment. Therefore, concerted effort will be made to measure adherence as described  
366 in Chapter 7. Adherence will be measured using both eye-care diaries and phone interviews with  
367 the primary caregiver. The diaries will be mailed from the DCC and the phone interviews will be  
368 conducted by DCC staff. Therefore, patient contact information must be provided to the DCC.  
369 The information requested includes name, home and work addresses, and home and work phone  
370 numbers for the mother, father and primary caregiver (if not the mother or father). The form will  
371 be kept secure at both the clinical center and the DCC. The information will not be shared with  
372 anyone outside the study. The informed consent document includes a description of the  
373 information being requested along with a rationale.

374  
375 Patient contact information should be verified at every visit after Day 1. Any changes should be  
376 recorded on the Patient Contact Information Form and kept in the patient's CRF Binder. When  
377 changes are made the form should be faxed to the DCC. The DCC will fax back a new version of  
378 the Patient Contact Information Form showing the current information.

379

380

381

## Chapter 3

382

### Treatment Regimens and Adverse Events

#### 3.1 Treatment Groups

384

385 Patients will be randomized to one of the following two treatments:

386

387 1) Cataract extraction and contact lens (CL) correction.

388 2) Cataract extraction, primary intraocular lens implantation (IOL), plus spectacles, as

389

needed.

#### 3.2 Surgical Protocols

391

392 Surgery will be performed only by a certified investigator (see Chapter 8) at an IRB-  
393 approved hospital after completion of the randomization procedure using one of the two  
394 following protocols. The Acrysof 6mm acrylic IOL (SN60AT, MA60AC) is covered by  
395 FDA IDE # G020021.

396

397 Thirty (30) minutes prior to surgery, the pupils should be dilated with either cyclogyl  
398 (0.5% or 1.0%) and 2.5% neosynephrine or cyclomydril. The drops may be repeated on  
399 two occasions, every 5 minutes.

##### 3.2.1 Surgical Protocol for Infants Randomized to Contact Lens Group

401

- 402 • The vitreous-cutting instrument will be used to create a mechanized anterior  
403 capsulotomy that is 5 mm or greater in size. The lens nucleus and cortex will be  
404 aspirated with the vitreous-cutting instrument.
- 405 • The vitreous-cutting instrument will be used to create a posterior capsulotomy that is  
406 4 mm or greater in size. An anterior vitrectomy will be performed through the  
407 posterior capsulotomy. All of the vitreous that prolapses into the anterior chamber  
408 and about 1/3 of the vitreous in the vitreous chamber should be excised.
- 409 • The two limbal stab incisions will each be closed with a 9-0 or 10-0 synthetic  
410 absorbable suture.
- 411 • One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in  
412 the operated eye, which will then be patched.

413

##### 3.2.2 Surgical Protocol for Infants Randomized to IOL Group

415

- 416 • An anterior capsulotomy 5 mm or greater in size will be made either manually with  
417 capsulorhexis forceps or in a mechanized manner with a vitreous cutting instrument.
- 418 • The lens nucleus and cortex will be aspirated with a vitreous cutting instrument.
- 419 • If posterior lentiglobus is present with a pre-existing opening in the posterior capsule  
420 or an opening was created iatrogenically during cataract surgery, the posterior  
421 capsulotomy should be enlarged to 4 mm and an anterior vitrectomy (cutting speed >  
422 400) should be performed through the limbal incision.

- 423 • The wound will be enlarged and the anterior segment filled with a viscoelastic agent.  
424 An AcrySof IOL (SN60AT) will be implanted into the capsular bag.  
425 If both haptics cannot be implanted into the capsular bag, An MA60 IOL should be  
426 implanted into the ciliary sulcus (subtract 1D from the calculated power).  
427 • The scleral tunnel incision will be closed with interrupted 9-0 or 10-0 synthetic  
428 absorbable sutures  
429 • The viscoelastic agent will be removed with an irrigation-aspiration instrument  
430 • The infusion cannula will be left in a limbal stab incision.  
431 • A stab incision will be made 1.5 - 2.0 mm posterior to the limbus  
432 • A vitreous cutting instrument will be inserted through this incision site. A central  
433 posterior capsulotomy, 4 mm or greater in size, will be created while the anterior  
434 chamber is infused with BSS or BSS Plus. About 1/3 of the vitreous immediately  
435 behind the IOL will also be excised. The vitreous cutting instrument will then be  
436 removed and the stab incision will be closed with a 7-0 or 8-0 synthetic absorbable  
437 suture or a 9-0 nylon suture.  
438 • One drop of 0.5% or 1% atropine and an antibiotic-steroid ointment will be place in  
439 the eye and the eye will be patched.

### 440 3.2.3 IOL Power Selection

441  
442 The IOL power will be determined in the operating room based on biometry and  
443 keratometry readings. After obtaining keratometry and axial length measurements for  
444 both eyes, a look-up table or an IOL calculator based on the Holladay I formula will be  
445 used to calculate the IOL power that will provide an 8D undercorrection for infants 4-6  
446 weeks of age and a 6 D undercorrection for infants older than 6 weeks; IOL powers may  
447 go up to 40D.  
448

### 449 3.3 Postoperative Medical Therapy

450  
451 For both the IOL Group and the Contact Lens Group, at a minimum, topical prednisolone  
452 acetate 1% should be instilled in the pseudophakic eye 4 times a day for 1 month  
453 following cataract surgery. If significant inflammation exists in the anterior chamber (2+  
454 or greater) or if there are visually significant precipitates on the optic of the IOL, topical  
455 prednisolone acetate 1% can be used more often than 4 times a day and longer than 1  
456 month, but never longer than 6 months. A topical antibiotic should be instilled in the  
457 pseudophakic eye 3 to 4 times a day for 1 week following cataract surgery. Finally,  
458 atropine 0.5% or 1% should be instilled twice daily in the pseudophakic eye for 2 to 4  
459 weeks following surgery. Medications are instilled in the presence of a contact lens if  
460 applicable.  
461

### 462 3.4 Occlusion Regimen

463  
464 An adhesive patch will be worn daily over the phakic eye 1 hour/day per month of age  
465 until the child is 8 months old starting the second week following cataract surgery. The  
466 unoperated eye will then be patched all hours that the child is awake every other day or  
467 one-half the child's waking hours every day. Children should be encouraged to

468 participate in their normal activities during patching therapy. The occlusion regimen may  
 469 be modified or discontinued if it is felt to be in the best interest of the child and with the  
 470 approval of the Steering Committee. *In the event of patching failure, defined as*  
 471 *average daily patching less than 15 minutes in the previous 3 months, the Investigator*  
 472 *may initiate a trial of the use of an occlusive contact lens in the normal eye. This also*  
 473 *requires the approval of the Steering Committee and is intended as a temporary remedy*  
 474 *until the child will accept on-the-face patching.*

475

### 476 **3.4.1 Development of Patch Allergy**

477

478 If an allergy develops to occlusive patches, a cloth patch should be used, which will be  
 479 provided by the investigator. The cloth patch should be worn over the spectacle lens of the  
 480 phakic eye. If spectacles are not otherwise needed, plano glasses will be provided by the  
 481 study for this purpose.

482

## 483 **3.5 Contact Lens Correction**

484

### 485 **3.5.1 Type and Power of the Contact Lens**

486 Patients randomized to the Contact Lens group (aphakic patients) will be fit with a Silsoft  
 487 or rigid gas permeable (RGP) contact lens shortly after surgery. Initially, the eye will be  
 488 overcorrected by 2.0 D to provide a near point correction; at two years of age, the eye  
 489 will be corrected for emmetropia with a contact lens and spectacles with a +3 D bifocal  
 490 segment for near vision. Parents will be given a spare contact lens to minimize the  
 491 chance of the child's not having a contact lens to wear at all times. The goal will be to  
 492 dispense the initial contact lens by the one-week post-operative visit. If an accurate  
 493 refraction cannot be obtained at that time, a +32 D Silsoft or RGP contact lens should be  
 494 dispensed. Lens power should then be refined at the earliest opportunity and any  
 495 parameter changes assessed at each visit. If a Silsoft contact lens cannot be worn  
 496 successfully, a rigid gas permeable contact lens should be dispensed instead or vice versa.  
 497 No patients randomized to the IOL group (pseudophakic patients) will be corrected with  
 498 a contact lens.

499

#### 500 **3.5.1.1 Fitting Silsoft Contact Lenses**

501 Silsoft is a Bausch & Lomb brand of silicone elastomer contact lenses for the treatment  
 502 of aphakia. Silsoft lenses are available in five base curves and two diameters. The  
 503 parameters are:

504

#### 505 **Base Curve Range**

506 7.5mm (45.00D) to 8.3mm (40.62D) in 0.2-mm steps

507

508 <b><u>Powers (diopters)</u></b>	508 <b><u>Increments (diopters)</u></b>	508 <b><u>Diameters (mm)</u></b>
509 +12 to +20	509 1	509 11.3, 12.5
510 +20 to +32	510 3	510 11.3

511

512 Keratometric (K) readings should be recorded at the time of surgery. The Silsoft lens is  
513 fitted on or near the flatter of the two K readings. After selecting the base curve,  
514 fluorescein dye may be used with a hand-held slit-lamp or Burton lamp to assess the tear  
515 pattern under the contact lens. Since infant corneas are typically small and steep, the  
516 7.5mm base curve lens in the 11.3mm diameter will be used most often. Fluorescein  
517 patterns, lens movement and centration should be evaluated at each visit. Retinoscopy  
518 will be used to determine the final power.  
519

### 520 **3.5.1.2 Fitting Rigid Gas Permeable Contact Lenses**

521 Rigid gas permeable contact lenses will be a lenticulated, hybrid aspheric design  
522 manufactured in a high DK (92 or greater) material with two edge lift values. Parameter  
523 availability is virtually unlimited for base curves, diameters or powers. A diagnostic  
524 fitting set and a fitting nomogram has been developed based on the following basic fitting  
525 outline:  
526

#### 527 **Base Curve Selection:**

528 Fit 1.0 to 1.5mm steeper than flattest keratometry reading  
529

#### 530 **Diameter Range:**

531 7.8 to 9.5mm; mean=8.5mm

532 Lens power will be determined by retinoscopy over the diagnostic lens.  
533  
534

#### 535 **Determining RGP Specifications:**

536  
537 All eyes are to be fitted empirically utilizing diagnostic lenses. The diagnostic set of  
538 lenses used is based on a formula of base curve radius plus 1.3mm equals the lens  
539 diameter. The trial lenses are of high plus powers and lenticulated. The anterior optical  
540 zone diameter corresponds to the posterior optical zone size, which equals the base curve  
541 radius in millimeters. The anterior optical size is often reduced in size to decrease lens  
542 mass. This reduction in mass not only increases the oxygen transmissibility; it  
543 significantly influences the physical fit of the lens. However, the anterior optical zone  
544 diameter must remain large enough for full pupil coverage in all gazes. The chosen base  
545 curve is one that reveals approximately thirty microns of positive tear power  
546 (approximately one diopter steeper than central keratometry); fulcrum or “grip” points  
547 achieved in the mid-peripheral cornea, adequate edge lift 360 degrees at the lens edge,  
548 and a central position. A base curve that exceeds this amount of vault can result in  
549 corneal edema due to poor tear film replenishment. The amount of corneal eccentricity in  
550 these patients seems to be a factor. The normal adult cornea flattens from the center in a  
551 non-linear fashion. This rate of flattening or eccentricity is lower in infant corneas  
552 compared to the normal adult cornea. This statement is based solely on the interpretation  
553 of fluorescein patterns of RGP lenses on the infant cornea. The amount of axial edge lift  
554 of the lens is one of the adjustments that can be made during the fitting and refitting  
555 process. The axial edge lift is often increased to loosen the lens on the cornea. With this  
556 method of empirical fitting, we are not biased by the central keratometry measurements

557 performed under anesthesia at the time of surgery. In addition, the central keratometry is  
558 not an indicator of the amount of corneal eccentricity.

559  
560 The diameter of the RGP lens varies with corneal diameter. The diameter of the lens  
561 should be large enough to maintain centration and stability. The diameter can be  
562 increased without an increase in center thickness by decreasing the anterior optical zone  
563 diameter; however, a larger diameter with the same base curve will fit tighter. Lens  
564 parameters are adjusted to avoid a center thickness that exceeds 0.50mm, as lens  
565 thickness affects the color, gas permeability, and weight of the lens.

### 566 **Diagnostic Fitting Kits**

567  
568  
569 A diagnostic fitting set will be used to determine lens parameters for each patient. The  
570 diagnostic lenses will be manufactured without a UV filter. This will allow the  
571 practitioner to better evaluate the fluoroscein pattern without the aid of a wratten filter.  
572 The diagnostic set will contain lenses with the following parameters:  
573

<b>Diopters/MM</b>	<b>Power</b>	<b>Diameter</b>	<b>Model</b>
45.00 / 7.50	+22.00	8.8	Star C
46.00 / 7.34	+22.00	8.6	Star C
47.00 / 7.18	+24.00	8.4	Star C
48.00 / 7.03	+24.00	8.3	Star C
49.00 / 6.89	+26.00	8.1	Star E
50.00 / 6.75	+30.00	8.0	Star E
52.00 / 6.49	+30.00	7.9	Star E

574  
575 \* Star C has a “looser” axial edge lift value than Star E  
576

### 577 **3.5.2 Contact Lens Failure and Secondary IOL Implantation**

578 A child will be considered to be a contact lens failure if he or she wears a contact lens for  
579 less than 4 hours a day on average over a period of 8 consecutive weeks. Ideally, the  
580 child will undergo a trial with both a Silsoft and rigid gas permeable contact lens. As a  
581 last resort, a custom soft contact lens may be worn.

582 Aphakic spectacles may be worn as necessary, for example, between trials with the  
583 different types of contact lenses.

584  
585 Before an IOL implantation is done, the investigator should complete a “Request for  
586 Secondary IOL Implantation” form to the DCC. **The approval of the steering  
587 committee is required before the secondary IOL implantation is performed.** This  
588 approval is required for all patients for the entire duration of the study, including after the  
589 patient has had the visual acuity assessment at one year of age.

590  
591 Unless the best interests of the child are at stake, every effort should be made to delay an  
592 IOL implantation in a child assigned to contact lens treatment until after the visual acuity  
593 assessment by the traveling examiner is done at approximately 12 months of age. Note



594 that the time window for the assessment is 10-14 months of age with 11-13 months of age  
595 preferred. If the IOL implantation must be done before 10 months of age, then the visual  
596 acuity testing center should be consulted to determine if a visual acuity assessment could  
597 be done in that particular patient.

598  
599 Ultimately, we plan to compare the two treatments for aphakia (IOL vs Contact Lens)  
600 based on optotype visual acuity measured when the child is 4-5 years of age. Optotype  
601 visual acuity is a more definitive measure of visual function. Therefore, it is critical to  
602 avoid secondary IOL implantation in patients assigned to the contact lens group until the  
603 optotype visual acuity can be done.

604  
605 IOL for Secondary IOL Implantation: Either PMMA or ACRYSOF IOLs may be used  
606 for secondary IOL implantation. In most cases the IOL should be implanted in the ciliary  
607 sulcus after severing all posterior synechiae. If the anterior and posterior capsules can be  
608 separated easily and the Soemmerring ring can be aspirated, the IOL can be placed into  
609 the capsular bag. If the IOL is placed in the sulcus, the IOL optic should be between 6  
610 and 7 mm in diameter and the overall diameter of the IOL should be between 13 and 14  
611 mm. If the IOL is placed into capsular bag, the optic diameter should be between 5.0 and  
612 6.0 mm with an overall diameter between 12 and 13 mm. Only FDA approved IOLs will  
613 be used in the study. The power of the IOL for the secondary IOL implantation is at the  
614 discretion of the surgeon.

### 615 **3.6 Spectacle Correction**

#### 616 **3.6.1 Contact Lens Group (Aphakic Patients)**

##### 617 Aphakic Eye

618 Spectacles will not be initiated in the contact lens group until the children are two years of age, at  
619 which time they will be prescribed a "D" segment bifocal lens with a distance correction of  
620 emmetropia and near correction of +3 D, except for children who are deemed to be non-  
621 compliant with one or more types of contact lenses. An aphakic spectacle correction can be  
622 prescribed for these children as needed at any time.

#### 625 **3.6.2 IOL Group (Pseudophakic Patients)**

##### 626 Pseudophakic Eye

628 Infants randomized to the IOL group will be prescribed spectacles by the one-month post-  
629 operative visit if any of the following conditions exist:

- 630 - Hyperopia greater than 1 D
- 631 - Myopia greater than 3 D
- 632 - Astigmatism greater than 1.5 D

633 Below the age of 2 years, the aim will be to correct the refractive error to -2 D. At age 2 years or  
634 older the aim will be to have a distance correction of emmetropia with a near correction of +3 D.

635

#### 636 **3.6.3 Unoperated Eye for Patients in Both Treatment Groups**

637 The unoperated eye will be corrected with spectacles if one of the following conditions exists:

638 - Hyperopia > 5 D

639 - Myopia > 5 D

640 - Astigmatism > 1.5 D

641 The aim will be to correct the refractive error to between 0 and +3 D. If the eye does not have a  
642 refractive error exceeding the parameters listed above, a plano lens should be prescribed.

643

644

**645 3.7 Adherence (See Also Chapter 7)**

646 Adherence with patching and the wearing of the prescribed optical correction will be assessed by  
647 a telephone interview conducted by the DCC at a random time at approximately 3-month  
648 intervals. In addition, a one-week “eye care diary” will be kept to document adherence and will  
649 be completed annually at approximately 2 months after surgery and 1 month after the visual  
650 acuity assessment at 12 months of age and then annually at approximately 25, 37, and 49 months  
651 of age. A two-day “eye care diary” will be completed by the mother, with assistance from the  
652 clinical coordinator, at the 1 month follow-up visit and again at the age 12 months visual  
653 assessment visit.

**654 3.8 Adverse Events/Risks****655 3.8.1 Risks of Lensectomy**

656  
657 A lensectomy is the standard means of removing a cataract in a child. A lensectomy is known to  
658 increase the risk of elevated intraocular pressure (glaucoma), retinal detachment, and a  
659 misshapen pupil.

660

**661 3.8.2 Risks of IOL Implantation**

662

663 Implanting an IOL in an infant's eye increases the risk of membrane formation across the pupil.  
664 These eyes are also at increased risk of having lens material reform. In some cases, this material  
665 may extend across the pupillary space and interfere with the vision of this eye. In either case, a  
666 reoperation may be necessary to remove the proliferating tissue. In some cases the IOL may  
667 become dislocated; it may need to be repositioned surgically.

**668 3.8.3 Risks of Contact Lenses**

669

670 Contact lenses increase the risk of bacterial keratitis particularly when worn on an extended wear  
671 basis. In addition, a corneal abrasion may occur at the time of lens insertion or removal.

**672 3.8.4 Risks of Occlusion Therapy**

673

674 The risks of occlusion therapy are limited to irritation of the skin. Removal of the patch every  
675 other day and treating the skin with emollients should be an effective treatment. *Also, Milk of*  
676 *Magnesia may be applied to the skin and allowed to dry before placing the patch.*

**677 3.8.5 Reporting Adverse Events**

678

679 At each follow-up examination, a check will be made for adverse events. The following events  
680 would be considered serious unexpected adverse events: glaucoma, retinal detachment,  
681 endophthalmitis, IOL subluxation, persistent corneal edema, bacterial keratitis. The following  
682 events would be considered minor and expected after cataract surgery in infants: corneal  
683 abrasion, transient corneal edema, wound leak, corectopia, hyphema, IOL capture, pupillary  
684 membrane, transient raised IOP, lens re proliferation into the visual axis.

685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711

These adverse events or any other serious vision threatening complications are to be noted on an Adverse Event Form that is to be faxed immediately upon completion to the DCC. A similar procedure will be followed if an adverse event is discovered at times other than a regularly scheduled follow-up examination.

### **3.8.6 Data Safety and Monitoring Committee (DSMC)**

An independent DSMC appointed by the National Eye Institute will be responsible for monitoring patient safety and study performance. The DSMC will meet semiannually to review accumulated data and can request interim reports as deemed necessary. The DSMC consists of two pediatric ophthalmologists who are not affiliated with the study, two biostatisticians not affiliated with the study (one of whom will serve as chair), a pediatric vision assessment professional, and *the mother of a child who had bilateral congenital cataracts* serving in the role of patient advocate. An NEI representative will serve as an ex officio member. The two pediatric ophthalmologists on the DSMC will be supplied with monthly reports of adverse events.

### **3.8.9 Medical Monitor**

In addition to the DSMC, an Emory ophthalmologist will serve as medical monitor. This individual serves as a resource for the DCC and will review adverse events on a monthly basis. The medical monitor will alert the Data and Safety Monitoring Committee if he determines, based on clinical judgment, that patient safety is jeopardized.

## Chapter 4

### Patient Follow-up, Visual Acuity Assessment, and Reoperations

#### 4.1 Follow-up Examination

The follow-up examination schedule approximates standard clinical practice. More frequent examinations may be performed at the discretion of the investigator. This will likely be the case if complications develop during the postoperative period.

#### 4.2 Follow-up Examination Schedule

Follow-up examinations may be performed as frequently as desired by the surgeon during the 3-month interval following cataract surgery. But at a minimum the child should be examined one day, one week, 1, and 3 months following cataract surgery. Thereafter, examinations will be performed by the investigator at 3-month ( $\pm 2$  weeks) intervals. An examination under anesthesia will be performed 2-4 weeks before the visual acuity assessment at 12 months of age; all other examinations will be performed in the office. Grating acuity estimates using the Teller Acuity Cards will be obtained at age 12 ( $\pm 2$ ) months by a trained examiner who will travel to each study site. Each patient will have undergone an EUA two weeks prior to these grating acuity assessments to ensure that the patient is wearing the appropriate optical correction when tested by the traveling examiner. The traveling examiner will not be informed of the clinical status of the patient and will not have participated in the clinical treatment of any of the patients.

#### 4.3 Follow-up Examination Procedures

##### 4.3.1 Routine Examinations

Routine examinations will be performed by the clinical investigator and will include the following:

- Qualitative visual acuity
- Motility assessment by the alternate prism and cover test, Krinsky test, or Hirschberg light reflex test
- Biomicroscopy or pen-light examination of the anterior segment and pupils
- Retinoscopy with hand-held lenses or phoropter
- Indirect ophthalmoscopy of the fundus
- A visit with the contact lens professional for children in the CL arm of the study

##### 4.3.2 EUA at 2-4 Weeks Prior to Visual Acuity Assessment at 12 Months of Age

The following studies are to be performed during the examination-under-anesthesia.

- 750 1. Tonometry, immediately after induction of general anesthesia, using a pneumotonometer,  
751 tonopen or Perkins tonometer.
- 752 2. Measurement of the horizontal corneal diameter using calipers.
- 753 3. Biomicroscopy using a hand-held slit lamp.
- 754 4. Keratometry of both eyes - Ideally a handheld autokeratometer should be used to obtain the  
755 K readings such as the Alcon Renaissance Hand Held Keratometer, but if this is unavailable a  
756 manual keratometer may be used. At least two keratometry measurements should be taken in  
757 both the affected and unaffected eyes to ensure that the results are accurate; the 2 average K  
758 readings should be within 1 D of each other. If the two average K readings are more than 1 D  
759 different, then make a third measurement and find the average of the two closest K readings.
- 760 5. Refraction using retinoscopy of the operated eye and of the fellow eye (cycloplegic).
- 761 6. Examination of the retina and optic nerve using indirect ophthalmoscopy.
- 762 7. B-scan ultrasonography if the retina and optic nerve cannot be visualized with indirect  
763 ophthalmoscopy.
- 764 8. A-scan biometry of both eyes using immersion if possible – take the measurement from the  
765 scan with the best wave forms (i.e., highest peaks with a perpendicular retinal spike) or, if  
766 applanation biometry is used, the A-scan with the greatest AC depth. Choose the phakic or  
767 aphakic setting on the ultrasound unit when obtaining the axial length measurements. The axial  
768 length measurement from the affected eye with the deepest anterior chamber depth and a 90  
769 degree angle between the baseline and the retinal spike should be recorded.

770

#### 771 **4.4 Visual Acuity Assessment (Primary Study Outcome)**

772 A traveling examiner will perform an outcome examination at approximately age 12 months.  
773 The target testing age will be 12 months with an acceptable range of 2 months on either side of  
774 this target. Ideally, the testing will be conducted within one month of the target age (11-13  
775 months of age). The reason for this stipulation is that monocular testing becomes increasingly  
776 difficult after 12 months of age because the infants are less and less tolerant of wearing a patch.  
777 Although the infants enrolled in this study are experiencing patching on a routine basis to treat  
778 their amblyopia, the testing situation is more stressful and their cooperation cannot be assured.  
779 The original testing session should be scheduled within the 2-month time window (11-13 months  
780 of age) if at all possible. This will also allow for the possibility of rescheduling and ensure that  
781 the testing is still within the stipulated 4-month window (10-14 months of age).

782

783 The examiner and the study center coordinator will work closely together to schedule the visual  
784 acuity assessment visits at a mutually agreed upon time within the time window. We anticipate  
785 good cooperation from the parent(s) in scheduling this visit. They will be aware of the  
786 specialized attention their child is receiving from the traveling examiner and will be informed of  
787 the importance of this particular assessment.

788

789 At clinics where the Teller Acuity Cards are routinely used for clinical purposes, the  
790 investigators are advised not to use the cards to evaluate the child's acuity for clinical purposes  
791 on the same day as the traveling examiner is collecting data for this study.

792

793 The patient will be examined during the EUA 2 to 4 weeks prior to the acuity testing. The  
794 purpose of this examination will be to ensure that the patient is wearing the most accurate optical

795 correction measured at the EUA. It is very likely that the optical correction in these patients will  
796 change significantly between the 9- and 12-month examinations. It will be the responsibility of  
797 the clinic coordinator to ensure that any required changes in optical correction are in place prior  
798 to the acuity testing. The clinic coordinator will assist the parent(s) in obtaining new spectacles  
799 or contact lenses as required and assure that these are available and in place before the acuity  
800 testing.

801

#### 802 **4.4.1 Preparation for Outcome Assessment Examination**

803 Because of the time and expense involved with the traveling examiner's visiting clinical sites, it  
804 is imperative that the examiner and patient's schedules be carefully coordinated to avoid either's  
805 being inconvenienced. The clinic coordinator should contact the Vision Testing Center at least 3  
806 months prior to the time the outcome assessment is to be performed. The Vision Testing Center  
807 and the clinic coordinator will agree on several possible dates for the outcome assessment. *It*  
808 *will be necessary to coordinate the acuity testing date with the EUA date, so both appointments*  
809 *need to be scheduled at the same time. Surgical time may be the limiting factor if the schedules*  
810 *are not made well in advance. If for any reason the EUA date needs to be rescheduled (the*  
811 *child is sick, family crisis), the coordinator will need to work carefully with the*  
812 *Parent/Caregiver as well as the Vision Testing Center to coordinate alternate dates. The*  
813 *Acuity Test Date should be agreed upon between the Clinical Center and the Vision Testing*  
814 *Center prior to determining the EUA date.* The clinic coordinator will then contact the parent(s)  
815 of the child to be tested and determine which date would be best for that patient. After  
816 confirming this date, the Vision Testing Center will be notified of the date for the examination.  
817 One month prior to the appointment, the clinic coordinator will send a reminder to the patient in  
818 the mail. In addition, information will be included in this mail giving detailed instructions as to  
819 what will happen at the appointment and what needs to be done to prepare for the appointment.  
820 One week before the appointment, the clinic coordinator will call the parent(s) of the child to  
821 confirm the appointment. Finally, early on the day before the outcome appointment, the clinic  
822 coordinator will again call the parent(s) of the patient to confirm the appointment. *It will also be*  
823 *important for the local site PI to contact the Parent/Caregiver by phone to remind them of the*  
824 *acuity testing visit. This personal contact is intended to stress the importance of this particular*  
825 *visit to the Parent/Caregiver and to assure their attendance.* If the parent(s) indicate after either  
826 of these telephone calls that they will not be able to keep the appointment, the clinic coordinator  
827 will immediately notify the Vision Testing Center so the traveling examiner can modify his or  
828 her travel plans.

829 The patient will have been examined two *to four* weeks prior to the acuity testing date, as stated  
830 above, to ensure proper refractive correction. The clinic coordinator will assist the parent(s) in  
831 obtaining new spectacles and/or contact lenses prior to the acuity testing as needed. The  
832 parent(s) will be called the night before the examination to remind him/her of their appointment.

833

#### 834 **4.4.2 Protocol for Resolution Acuity Testing Using the Teller Acuity Cards**

835

##### 836 **General**

837 Prior to the traveling examiner's meeting the patient, the clinical investigator or clinical  
838 coordinator will check to be sure the child is wearing the optical correction prescribed and

839 completes the Teller Acuity Card Assessment – Site Coordinator Form. The traveling examiner  
840 does not review the patient’s chart prior to conducting the visual acuity assessment.

841

### 842 **Conduct of Grating Acuity (Teller Acuity Card) Assessment at 12 Months of Age**

843 Monocular grating acuity will be assessed by the traveling examiner with the Teller Acuity  
844 Cards. The examiner will bring a complete set of Vistech Teller Acuity Cards to the study center.  
845 Dr. Hartmann will accompany the traveling examiner on the initial visit to each site. She will be  
846 responsible for assuring that all testing conditions are satisfied. She will work directly with the  
847 site clinical coordinator prior to this initial visit and review the requirements for the physical set-  
848 up for the grating acuity testing. Sufficient time will be allocated at the initial visit to review the  
849 location of the testing within the clinic and to assure that all protocol requirements are being met.  
850 For example, if lighting is inadequate, the clinical coordinator will assist Dr. Hartmann in  
851 obtaining the necessary extra devices needed for indirect illumination in the testing room.

852

### 853 **Lighting Conditions for the Grating Acuity Testing**

854 Room lighting is usually sufficient to provide a luminance of the screen of at least 10 cd  
855 (candela) /m<sup>2</sup> . This luminance will be verified by the traveling examiner at the time of the  
856 testing. The traveling tester will bring a luminance meter for this purpose. Dr. Hartmann will  
857 supply the luminance meter for the study from her laboratory equipment. Luminance must be  
858 uniform across the screen and the acuity cards, so that shadows do not distract the child’s  
859 attention from the test gratings. When the existing lighting does not meet these conditions,  
860 additional lights will be used and are directed toward the ceiling of the room to provide indirect  
861 illumination of the screen and cards.

862

### 863 **Location of Grating Acuity Assessments**

864 Testing is conducted in a space that is at least 6’ X 6’ and is as free as possible from distracting  
865 objects or noises. A portable screen that allows horizontal card presentation is used to block out  
866 any remaining distractions in the room. This screen may be either a table-top model as  
867 manufactured by Vistech (for those clinical centers who already own the screen) or a free-  
868 standing model designed at the Vision Testing Center and shipped to the clinical site. At this age  
869 the child will be seated in the parent’s lap for the testing. The adult will be screened from the  
870 card using a shield placed at the adult’s eye level, to avoid assisting the child in a response.

871

### 872 **Order of Testing of Eyes**

873 The aphakic or pseudophakic eye will be tested first so that in case the infant becomes  
874 uncooperative during the test, the affected eye will have a measurement. Every effort will be  
875 made to test both eyes, including taking a break, even to the extent of postponing the test until  
876 the next day.

877

### 878 **Patching**

879 Parents will be instructed to have the child wear the patch to the visual acuity assessment to  
880 avoid the child becoming uncooperative at the exam when the patch is first put on. The visual  
881 acuity examiner will inspect the patch to insure that it is properly positioned. A Coverlet patch  
882 will be used as an occluder and the traveling examiner will be responsible for having a supply of  
883 these patches. The patch will be used for all children except those with nystagmus. Children



884 with nystagmus should have the eye that is not being tested covered with a high plus lens, e.g.  
885 +10 D.

886  
887

### 888 **Test Distance**

889 The standard test distance for 12-month-old infants is 55 cm, measured from the screen to the  
890 child's eyes. Children with poor visual acuity may require testing at a nearer distance.  
891 Recommended choices for nearer distances are 38 cm (the distance used with infants younger  
892 than 6 months), 19 cm, and 9.5 cm. Use of 19 cm or 9.5 cm allows easy calculation of acuity  
893 scores. At 19 cm, the acuity value is one-half that listed in the Vistech Teller Acuity Card  
894 manual for 38 cm (e.g., a score of 6.5 cycles/cm provides an acuity estimate of 4.9 cycles/degree  
895 at 38 cm and an acuity estimate of 2.45 cycles/degree at 19 cm). Similarly, an acuity value  
896 obtained at 9.5 cm is one-quarter that listed in the Vistech manual for 38 cm (e.g., a score of 6.5  
897 cycles/cm at 9.5 cm indicates an acuity estimate of 1.23 cycles/degree).

898

### 899 **Test Duration**

900 For most 12-month-old infants Teller Acuity Card testing requires less than 5 minutes per eye.  
901 Infants with severely impaired vision may require as much as 10 to 15 minutes per eye.

902

### 903 **Recording Results**

904

### 905 **Data Form**

906 The examiner records grating acuity results on a data sheet identified as the Teller Acuity Card  
907 Assessment Form. The original of this form is retained by the traveling examiner and stored at  
908 the Visual Acuity Testing Center. A copy is faxed to the DCC from the clinical site after the  
909 completion of the exam. This form is not left at the Clinical Center or retained in the patient's  
910 binder.

911

912

### 913 **4.4.3 Resolution Acuity Testing Procedure (Teller Acuity Cards)**

914

#### 915 **Usual Testing Method for Using the Teller Acuity Cards**

- 916 • Start with two stacks of cards
- 917
- 918 • On the top of one stack is the 1.3 cycles/cm card. Beneath this card are acuity cards  
919 containing higher spatial frequencies (narrower stripes) arranged sequentially from low to  
920 high spatial frequency
- 921
- 922 • The second stack contains spatial frequencies lower than 1.3 cycles/cm (wider stripes)  
923 arranged sequentially from high to low spatial frequency (smaller to larger stripes).
- 924
- 925 • This provides a continuous series of gratings in the two stacks. Therefore, in order to  
926 proceed sequentially to higher or lower spatial frequency gratings, the observer has only  
927 to move the top card in one stack to the top of the other stack and pick up the next card in  
928 the first stack.

929

930 • Check the lighting of the cards with the light meter that is provided with the Teller Acuity  
931 Cards or a luminance meter. It is sometimes difficult to get 10 cd/m<sup>2</sup> or greater under  
932 normal office lighting and additional lights should be added.

933

934 • If supplemental lights are needed, use indirect sources (e.g., directed toward the ceiling),  
935 in order to avoid casting uneven shadows on the cards.

936

937 • Seat child (on the parent's lap) 55 cm from cards

938

939 • Testing Procedure

940

941 A. Testing begins with the 1.3 cycles/cm card

942

943 B. During the testing the examiner uses his or her face or a toy to attract the child's  
944 attention to the opening in the screen. Initially, the examiner shows the child the  
945 1.3 cycles/cm card. The grating on this card is easily detected by normal children  
946 12 months of age and older. After the child responds to the card, the examiner  
947 rotates the card by 180 degrees, to position the acuity grating on the opposite side  
948 of the card (left versus right). The examiner does not look at the card between  
949 presentations and does not know the exact location of the stripes. The examiner  
950 has made a guess as to the location of the stripes based on the child's fixation  
951 response to the initial presentation and anticipates that the child will look at the  
952 opposite side of the card once it is rotated 180 degrees. The examiner again places  
953 the card up to the opening in the screen and watches the child's response.

954 Typically, the child's eye movements will indicate clearly that the child can detect  
955 the grating. That is, the child will show clear fixation of one side of the card upon  
956 the first presentation, and after the card has been rotated the child will show clear  
957 fixation of the opposite side of the card.

958

959 C. If the examiner judges that the child can see the grating, the examiner is permitted  
960 to look at the front of the card to confirm that the grating is actually on the side to  
961 which the child responded. After the child has shown a clear response to the 1.3  
962 cycles/cm grating, and the examiner has confirmed the accuracy of his/her  
963 judgment, the examiner proceeds to show the child cards containing sequentially  
964 higher spatial frequency gratings until no response is obtained from two  
965 successive gratings. Acuity threshold is estimated as the highest spatial frequency  
966 grating (narrowest stripe width) to which the child shows a clear response.

967

968 D. During sequential presentation of the cards, the examiner is required to show each  
969 acuity card to the child at least twice, once with the grating in each of the two  
970 possible test locations (left and right) before making a decision as to whether the  
971 child can see the grating. With low spatial frequencies (wide stripes), the child's  
972 response is usually so clear that only these two presentations are required. As the  
973 stripes on the cards approach and go below the child's acuity threshold, it is often

974 necessary for the examiner to present a card more than two times to reach a  
975 decision concerning whether or not the child is responding to the grating. IT IS  
976 ESPECIALLY IMPORTANT WHEN PRESENTING GRATINGS NEAR  
977 THRESHOLD THAT THE EXAMINER REMAIN MASKED TO THE  
978 LOCATION OF THE GRATING SO THAT HIS OR HER JUDGMENT IS  
979 BASED SOLELY ON THE CHILD'S RESPONSE. The examiner must be  
980 careful to make a decision concerning whether or not the child can see the grating  
981 before looking at the front of the card to determine actual grating location. The  
982 examiner can postpone making a decision about the child's response and present  
983 an easy card at any point in the testing to ensure that the child is continuing to  
984 cooperate with the testing and to reassure both herself and the child that there is  
985 something to look at on the cards. In other words, an important feature of the  
986 procedure is that the examiner is not required to show the cards in strict sequential  
987 order. As threshold is approached, a child will often become bored, distracted, or  
988 fussy. When this happens, it is helpful to return to a low spatial frequency grating  
989 (wide stripes) to which the child showed a clear response earlier in testing.  
990 Another clear response to this low spatial frequency grating is a good indicator  
991 that the child's reaction to the higher spatial frequency grating was related to his  
992 or her inability to see the grating, not to a general lack of attention. The  
993 examiner's judgment is always whether or not the child can see the grating pattern  
994 (Yes or No). This is a subjective judgment that is highly accurate in a well-trained  
995 examiner. It is NOT based on the number of "correct" fixations per se, but rather  
996 an overall gestalt judgment on the part of the examiner.  
997

998 E. The examiner is required to go back and retest the "threshold" Teller Acuity Card  
999 after determining that the child cannot detect the next smaller grating. If the  
1000 examiner is not convinced that the child resolves the originally specified  
1001 "threshold" grating, the examiner is required to go back another grating and  
1002 confirm that the child can see that grating. If the examiner is not convinced that  
1003 the grating initially thought of as "threshold" can be discriminated by the child,  
1004 then s/he is required to find the grating that **is** the threshold.  
1005

1006 F. When the examiner is satisfied that he or she has found the boundary between  
1007 spatial frequencies seen by the child and spatial frequencies not seen by the child,  
1008 the test is ended and the examiner records the child's acuity as the highest spatial  
1009 frequency (narrowest stripe width) that he or she judged that the child could see.  
1010

### 1011 **Testing Children with Very Poor Acuity**

1012 Children with poor acuity will not respond to the 1.3 cycles/cm grating. If this happens, the  
1013 examiner uses the second stack of cards, i.e., the cards with the lower spatial frequency gratings  
1014 (wider strip widths). The examiner begins with the lowest or one of the lowest spatial frequency  
1015 gratings in this stack and then proceeds to higher spatial frequency gratings until he or she judges  
1016 that acuity threshold has been reached. If no response to any of the standard acuity cards is  
1017  
1018

1019 obtained at the 55 cm test distance, the examiner will test at 38 cm. If no response to any of the  
1020 standard acuity cards is obtained at the 38 cm test distance, the examiner will test at 19 cm.

1021  
1022 Some children may not respond to any of the acuity cards when they are presented behind the  
1023 screen, even when the child is moved up to 38 cm. If this happens, the examiner should try  
1024 testing the child without the screen. To test without the screen, the examiner sits in front of the  
1025 child, carefully measures the test distance, and then shows the child various cards until an  
1026 estimate of acuity can be made. Initially, the examiner tries a test distance of 55 cm. If no  
1027 response is obtained, the examiner moves in to 38 cm. If no response is obtained at 38 cm, the  
1028 examiner will try the test at 19 cm. If no response is obtained at 19 cm, the examiner will try the  
1029 test at 9.5 cm. At 19 and 9.5 cm, examiners often find it easier to observe the child over the top  
1030 of the card rather than through the peephole.

1031  
1032 When testing without the screen, the examiner can position the card so that children who fixate  
1033 with some part of the retina other than the fovea can see the card. If a child has a horizontal  
1034 nystagmus, the examiner can hold the cards vertically, since it may be easier to distinguish  
1035 differential fixation of up versus down than left versus right in these children.

1036  
1037 Children who fail to respond to any of the standard acuity cards without the stage at 55, 38, 19,  
1038 or 9.5 cm should be tested with the Low Vision Acuity Card. This card contains a large (24 X 24  
1039 cm) patch of very wide stripes (2.2 cm/stripe) and is used to assess the presence versus absence  
1040 of pattern vision in these children. It is typically used without the stage. The Low Vision card  
1041 should be presented initially at 19 cm. If the child responds to this pattern, the examiner can  
1042 retest the child at farther distances, e.g., 38 cm and 55 cm. The final data recording will indicate  
1043 detection of the Low Vision card at the furthest distance.

1044  
1045 It is permissible to move the Low Vision Card and watch for a tracking response. However, other  
1046 Teller Acuity Cards should be kept stationary when they are presented.

1047  
1048 **4.4.5 Assignment of Visual Acuity for Patients Whose Vision is Below the Level That Can**  
1049 **Be Measured.**

1050  
1051 We are proposing to use any of four testing distances. We will initiate the testing at 55 cm. If the  
1052 infant cannot respond to the start card at this test distance as well as the largest stripe width, we  
1053 will move to the closer testing distance of 38 cm. If the infant still does not respond to the card  
1054 with the largest stripe at this distance, we will move to 19 cm, and finally 9.5 cm. When we test  
1055 at the closer distances of 19 and 9.5 cm it is likely that we will be testing away from the Acuity  
1056 Card Stage. At the test distance of 9.5 cm, the largest stripe width of 0.32 cy/cm yields a Snellen  
1057 equivalence of 20/6400 (2.5052 logMAR). We will not use the Low Vision Card under any  
1058 circumstances to provide a numerical estimate of visual acuity. If the infant does not respond to  
1059 the largest stripe at the shortest distance and we are unable to generate a numerical acuity  
1060 estimate in the standard manner (clinical method of adjustment), we will assign an acuity of  
1061 20/8860 (2.6464 logMAR). This corresponds to a 0.1412 logMAR decrease below 20/6400. The  
1062 interval 0.1412 is the mean of the intervals between the 20/910 (1.6580 logMAR) and the  
1063 20/6400 acuities of the Teller acuity cards at the 9.5 cm distance. Additional information that the

1064 tester will consider when assigning this low level of acuity will include the observed behavior of  
1065 the child relative to visual tasks, the qualitative visual assessment of the IATS physician, and the  
1066 parent's description of the child's behavior relative to visual tasks.

1067  
1068  
1069  
1070  
1071

1072 **Distinguishing Between LP and NLP When There is No Pattern Vision**

1073

1074 *Children who do not demonstrate any gross pattern vision using even the Low Vision Card*  
1075 *will be evaluated for the presence of light perception (LP). If the child does not respond to this*  
1076 *assessment, the vision in that eye will be classified as no light perception (NLP).*

1077

1078 *LP will be tested with a pen light, a Finoff light, or an indirect ophthalmoscope. Testing for*  
1079 *LP must take place in a darkened room. If using a pen light, which may not be very bright, the*  
1080 *room needs to be totally dark. If using a Finoff light or indirect ophthalmoscope, both of*  
1081 *which have bright lights, total darkness may not be necessary but it is still the ideal.*

1082

1083 *It is necessary to block all light from the eye not being tested for assessment of LP. It will be*  
1084 *necessary to use an eye patch as well as having the tester (or parent or helper) place the palm*  
1085 *of one hand gently but firmly over the eye patch occluding the eye not being tested. The light*  
1086 *should then be presented to the uncovered eye several times, from the front and from the sides.*  
1087 *The tester should watch for a consistent change in behavior that occurs only when the light is*  
1088 *being presented, (e.g., eye movement towards or away from the light, head turn towards or*  
1089 *away, or possibly just a quieting of behavior). If the child does not demonstrate a consistent*  
1090 *response to this presentation, the vision in that eye will be considered NLP.*

1091

1092 **Data Values for Low Vision, LP and NLP**

1093

1094 *We originally proposed the following method for assigning a logMAR value for patients who*  
1095 *fail to recognize the Teller acuity card with the largest stripe:*

1096

1097 *If the infant does not respond to the largest stripe at the shortest distance and we are unable to*  
1098 *generate a numerical acuity estimate in the standard manner (clinical method of adjustment),*  
1099 *we will assign an acuity of 20/8860 (-2.6464 logMAR). This corresponds to a 0.1412 logMAR*  
1100 *decrease below 20/6400. The interval 0.1412 is the mean of the intervals between the 20/910*  
1101 *(1.6580 logMAR) and the 20/6400 acuities of the Teller acuity cards at the 9.5 cm distance.*

1102

1103 *We now recognize that this method does not provide a distinction between some pattern*  
1104 *recognition, LP and NLP. We propose to assign -2.6464 logMAR for some pattern recognition*  
1105 *detected with the Low Vision card, -2.7876 logMAR for LP, and -2.9288 logMAR for NLP.*  
1106 *The values for LP and NLP were determined using the 0.1412 logMAR value described above.*

1107

1108

1109

**1110 4.4.6 Discontinuation of Contact Lens Prior to Traveling Examiner Examinations**

1111

1112 If a child randomized to CL correction discontinues CL use prior to the 12 month assessment and  
1113 has not received a secondary IOL, then the child will wear his aphakic correction in trial  
1114 spectacles for the examination by the traveling examiner.

1115

1116

1117

**1118 4.4.7 Discontinuation of Spectacles Prior to Outcome Examinations**

1119

1120 If a child in either the CL or IOL group discontinues the use of the glasses prescribed prior to the  
1121 outcome examination at 12 months, the glasses prescribed or the same prescription in trial  
1122 frames will be worn during the grating acuity assessment using the Teller Acuity Cards.

1123

**1124 4.4.8 Rescheduling Examinations When the Child is Uncooperative**

1125

1126 We will schedule up to three sessions to assess visual acuity for a child. If the child is  
1127 uncooperative for the first session, we will endeavor to schedule a second session on the same  
1128 day after the infant has had a lengthy break (several hours). If necessary, the second session will  
1129 be scheduled for the following day. If the second testing session is unsuccessful, we will request  
1130 that the parent return at a later date for the third session. We will not attempt three testing  
1131 sessions on the same trip. If the second session is on the same day, the third session will not be  
1132 on the following day. The third testing session will be scheduled at least one week after the  
1133 original testing session. If only one eye is to be tested at the third session (because the other eye  
1134 was successfully tested at the first or second session), then the third session will be scheduled  
1135 within 4 weeks of the original testing session. If necessary, Dr. Hartmann will accompany the  
1136 traveling tester to the third testing session, or possibly come by herself to conduct the testing. Dr.  
1137 Hartmann will make this decision in conjunction with the traveling tester and the site  
1138 coordinator. The site coordinator will be asked for an assessment of the need for a different tester  
1139 and an opinion of the parent's impression of the testing situation.

1140

**1141 4.4.9 Rescheduling Missed Examinations**

1142

1143 If a patient misses a study visit, the clinical coordinator should call the parent or legal guardian  
1144 of the patient the same day in an attempt to ascertain the reason for non-attendance for the  
1145 examination. If the parent/legal guardian can be reached, the clinic coordinator should  
1146 reschedule the appointment as soon as possible, however, every effort should be made to  
1147 accommodate the schedule of the parent. If the clinic coordinator cannot reach the parent after  
1148 three telephone calls at three different times of day on three different days over the course of no  
1149 more than one week at the primary telephone number, other ancillary telephone numbers listed  
1150 for the child should be used.

1151

**1152 4.4.10 Providing Physicians and Parents the Visual Acuity Assessment Results**

1153 The visual acuity test result will be communicated on a form to the physician on the day of the  
1154 exam along with a graph or table showing normative data by age. The physician can then discuss  
1155 the results of the test with the parents/caregivers.

1156

## 1157 **4.5 Reoperations**

1158

### 1159 **4.5.1 Post-Operative Complications**

1160

1161 Potential complications related to the cataract surgery, both in the IOL group and in the aphakic  
1162 group will be monitored. The time of recognition of the complication, the treatment of the  
1163 complication, and the results of treatment will be recorded and analyzed.

1164

1165 Reoperations by the investigator will be permitted during the immediate post-operative period  
1166 for any of the following complications:

1167

- 1168 1. **Wound leak** - A shallow or flat anterior chamber secondary to a wound leak that is  
1169 judged by the examiner as unlikely to undergo closure without surgical intervention.  
Any wound leak persisting for 48 hours will be surgically repaired.

1170

- 1171 2. **Poor IOL position** - IOLs that are poorly positioned will be surgically repositioned  
1172 under the following conditions: (1) the optic is subluxed out of the visual axis; (2) the  
1173 edge of the optic bisects the visual axis; (3) the haptic is displaced into the vitreous or  
1174 into the anterior chamber; (4) there is severe iris chafing; or (5). there is optic capture  
1175 by the pupil. If trauma is responsible for the poor IOL position this will be recorded.

1176

- 1177 3. **Retained lens cortex** - Surgical removal of residual lens cortex will be performed if  
1178 residual cortical material is felt to be responsible for excessive postoperative  
1179 inflammation (4+) that persists for 10 days despite the usual postoperative steroid  
1180 regimen. In the late post-operative period surgery will be performed for any  
1181 re proliferation of cortical material that blocks the visual axis.

1182

- 1183 4. **Hyphema** - Surgery will be performed for a hyphema under the following conditions:  
1184 (1) the hyphema is present for 3 weeks; (2) the hyphema occupies more than 50% of  
1185 the anterior chamber volume and glaucoma is present or (3) the intraocular pressure is  
1186 elevated to greater than 35 mmHg for more than 72 hours despite maximal medical  
1187 therapy.

1188

- 1189 5. **Endophthalmitis** - Vitreous culture and intravitreal antibiotic treatment will be  
1190 initiated for suspected endophthalmitis. The results of vitreous cultures and gram  
1191 stains will be recorded.

1192

- 1193 6. **Retinal detachment** - The choice of surgical procedure for retinal detachment will be  
1194 left to the discretion of the treating vitreo-retinal surgeon.

1195

- 1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215
7. **Pupillary Membrane** - Surgery to remove secondary membranes or vitreous opacities will be performed if the presence of the opacity is consistent with a decrease in the visual acuity potential to the 20/50 level in the judgement of the examiner.
  8. **Glaucoma** - The indication for glaucoma surgery is a sustained intraocular pressure (IOP) of 25 mmHg or greater while receiving maximal medical therapy including a  $\beta$ -blocker, Xalatan, and Trusopt, and persisting for more than two weeks after the discontinuation of topical steroids. Systemic carbonic anhydrase inhibitors are not to be used for more than two weeks and Alphagan and Iopidine are to be avoided. In addition, intraocular pressure above 21 mmHg with ANY of the following: visible and/or measurable enlargement of the cornea compared with the normal fellow eye, asymmetrical progressive myopic shift in the presence of corneal enlargement, and increased optic nerve cup-to-disc ratio of at least 0.2. The choice of surgical procedure will be left to the discretion of the treating surgeon.
  9. **Miosis or Corectopia** – A pupilloplasty will be performed if inadequate pupillary dilation precludes the performance of both an accurate refraction and an examination of the optic disc and fundus or if the pupil is so eccentric it is believed that it will compromise the visual acuity of the eye

#### 1216 **4.5.2 Strabismus Surgery**

1217 Strabismus surgery will be treated with commonly accepted medical practices and will be  
1218 performed when indicated. The treatment algorithm will be left to the discretion of the  
1219 Investigator.

1220



## Chapter 5

### Statistical Considerations

#### 5.1 Sample Size Estimate

The primary hypothesis to be tested in the IATS study is that the mean visual acuity for affected eyes at 12 months of age will be better for children that have an IOL implanted (pseudophakic group) than for children that do not have an IOL implanted and are treated primarily with a contact lens (aphakic group). To test this hypothesis, infants 28 to 210 days of age with a unilateral congenital cataract will be randomly assigned to one of the two treatments and visual acuity will be tested using Teller Acuity Cards at approximately 12 months of age.

IATS investigators conducted a pilot study on a convenience sample of 25 children at 5 clinical centers who had a monocular congenital cataract treated with an IOL or contact lens. A trained visual acuity examiner was sent to each of the 5 centers to standardize the visual acuity testing. The average age at the time of cataract surgery was 10 weeks (range = 2-23) and the average age at the time of the visual acuity exam was 19 months (range = 7-30). The mean  $\pm$  standard deviation of the visual acuity (logMAR) in the affected eyes was  $0.704 \pm 0.318$  for the pseudophakic group and  $0.873 \pm 0.312$  for the aphakic group.

The sample size estimate was made to detect a .2 logMAR difference (2 lines of Snellen visual acuity) between the mean visual acuity of the two groups. An estimate of the variance of the visual acuity was calculated from the pilot data above by pooling the observed variances of the two groups using the formula  $((n_1 - 1)s_1^2 + (n_2 - 1)s_2^2)/(n_1 + n_2 - 2)$ . The decision to pool was based on the similarity of the observed variances of the two groups as verified by an F-test ( $p = .97$ ). The pooled estimate of the standard deviation of the visual acuity was 0.315 logMAR. Rather than use this estimate in the sample size calculation, to be conservative we elected to use the standard deviation based on the upper one-sided 80% confidence limit for the variance. This limit is obtained from the formula  $(df \times s^2 / \chi^2_{df, \alpha})$  where  $df$  is the degrees of freedom for the estimate of the variance and  $\chi^2_{df, \alpha}$  is the value from a chi-square distribution with  $df$  degrees of freedom corresponding to a probability of  $\alpha$ . (If  $X$  is a chi-square random variable with  $df$  degrees of freedom, then  $\text{Probability}(X < \chi^2_{df, \alpha}) = \alpha$ ). In this case  $df = 23$  and  $\chi^2_{23, .2} = 17.19$ . The estimate for the standard deviation of the visual acuity in the affected eye that was used in the sample size calculations was .365 logMAR. The interpretation of this estimate is that we are 80% confident that the true standard deviation of the visual acuity in the affected eye is less than .365 logMAR.

The sample size estimate was based on the t test for comparing the means of independent groups. The difference in the means was set at .2 logMAR, the standard deviation was set at .365 for both groups, the Type I error was set at .05, the power was set at .8, a two-tailed alternative hypothesis was used and the standard deviations were assumed to be unknown and unequal. The resulting sample size estimate was 54 patients per group. As a final adjustment, we assumed that 5% of patients would be lost to follow-up before 1 year. This resulted in a sample size estimate of 57 patients per group for a total of 114 patients.

1265

**1266 5.2 Stratification**

1267

1268 The treatment in this study involves a complex surgical procedure; therefore, surgical skill and  
1269 technique could possibly have an effect on the outcome. Also, the age of the child at the time of  
1270 cataract surgery is thought to be an important factor for the visual acuity outcome with younger  
1271 children having a better prognosis.

1272

1273 Since some centers may have a relatively small number of patients, rather than stratifying by  
1274 individual center, the centers will be categorized into 3 groups and the randomization will be  
1275 stratified with the 3 groups. The 3 groups are: (1) Steering Committee Members: Emory U,  
1276 Indiana U, Duke U, MUSC; (2) Other centers that participated in a randomized pilot study: U of  
1277 Minn, Vanderbilt U, Dallas, Oregon U; (3) Remaining centers: USC, Harvard U, Miami,  
1278 Cleveland Clinic, Baylor U. In addition, patients will be stratified according to age with two age  
1279 groups, 28-48 days and 49-210 days.

1280

**1281 5.3 Statistical Power for Other Outcomes**

1282

**1283 5.3.1 Interocular Difference in Visual Acuity**

1284

1285 A secondary analysis will be a comparison of the mean interocular difference in visual acuity at  
1286 one year of age between the treatment groups. The interocular difference in visual acuity is an  
1287 assessment of the difference in visual acuity between the affected and unaffected eyes of each  
1288 patient.

1289

1290 In the retrospective pilot study, the mean (sd) of the interocular difference in visual acuity  
1291 (logMAR) was 0.260 (0.295) for the IOL group and 0.501 (0.279) for the Contact Lens group. A  
1292 point estimate for the standard deviation, based on pooling the data for the two groups, was  
1293 0.290 and the upper 80% confidence limit is 0.330.

1294

1295 With 0.330 for the standard deviation and with 54 patients per treatment group, the power of the  
1296 study is 0.88 to detect a 0.2 logMAR difference between the groups based on a two-sided t test  
1297 for comparing the means of independent groups with probability of a Type I error = 0.05.

1298

**1299 5.3.2 Ocular Complications**

1300

1301 The power for comparing the percent of patients who experience a complication (such as  
1302 strabismus) was determined by setting the difference between the two groups and then  
1303 calculating the percentages that would be symmetrical around 50%. This was done because for a  
1304 specific sample size the power will be the smallest when the percentages are symmetrical about  
1305 50%. Thus the power estimates are conservative. The power was calculated using a z-test for  
1306 comparing percentages with 54 patients per group and with the Type I error set at .05. For an  
1307 absolute difference of 20% (for example, 40% vs 60%) the power was .47. For absolute  
1308 difference of 27%, the power was 0.81. Therefore the study will have power of at least .8 for  
1309 detecting differences between the groups for the percentages of patients who experience

1310 complications if the percentages differ by 27% or more. In terms of estimation rather than  
1311 hypothesis testing, with 54 patients in each of the groups, the width of the 95% confidence  
1312 interval for estimating the percentage of complications varies from  $\pm 8\%$  to  $\pm 13\%$  as the  
1313 observed percentage varies from 10% to 50%. The confidence interval calculations were done  
1314 using the normal approximation to the binomial distribution.

1315

### 1316 **5.3.3 Parenting Stress**

1317

1318 A parenting stress assessment (the Parenting Stress Index and a disease-specific measure, the  
1319 Ocular Treatment Index) will be administered to parents at the 3-month follow-up visit and at the  
1320 first 3-monthly visit after the visual acuity assessment. Thus, the primary analyses will be a  
1321 comparison of the mean scores of the two treatment groups 3-months after surgery and when the  
1322 child is approximately 15 months of age. The statistical power of this comparison was  
1323 determined using the summary statistics from the Parenting Stress Pilot Study. The mean  $\pm$   
1324 standard deviation of the child domain scores were: Pseudophakic Group ( $99.2 \pm 16.6$ ), Aphakic  
1325 Group ( $110.5 \pm 25.9$ ). The sample size was 13 parents in each of the groups. Power was  
1326 calculated using the independent groups t-test with 54 parents per group, alpha set to .05, the  
1327 standard deviations set to 16.6 and 25.9, and a two-tail alternate hypothesis. Power was  
1328 determined for differences in the means of the groups based on a percent difference from the  
1329 mean score of the Aphakic Group. For example, the power to detect that the mean child domain  
1330 score of the Pseudophakic Group will be 10% less than the mean of the Aphakic Group, an  
1331 absolute difference of 11.1, is 0.75. For a 15% relative difference, the power is 0.98. There  
1332 appears to be adequate power to detect reasonable differences between the means of the two  
1333 groups. However, there are limitations in the estimates provided by the pilot study. In addition to  
1334 the small sample size, the pilot study included patients with diagnoses other than unilateral  
1335 congenital cataract. Also, there was a wide age range among the patients at the time of the test (5  
1336 months to 5 years).

1337

## 1338 **5.4 Statistical Analysis**

1339

### 1340 **5.4.1 Visual Acuity in the Affected Eye**

1341

1342 The primary analysis will be a comparison of the treatment groups based on the mean visual  
1343 acuity in the affected eye at 12 months of age. The comparison will be made using an  
1344 independent groups t test. Also, 95% confidence intervals will be computed for the mean visual  
1345 acuity in each group and for the difference in the means. If the data indicate that a parametric test  
1346 is not appropriate then a non-parametric test will be done. The analysis will be done following  
1347 the intention to treat principle. That is, the patients will be grouped according to the treatment to  
1348 which they were originally assigned.

1349

### 1350 **5.4.2 Interocular Difference in Visual Acuity**

1351

1352 A secondary analysis will be a comparison of the treatment groups based on the mean interocular  
1353 difference in visual acuity between the affected and unaffected eyes of patients at 12 months of

1354 age. The same methods will be used as described for the primary analysis of the visual acuity in  
1355 the affected eyes.

1356

1357

### 1358 **5.4.3 Ocular Complications**

1359

1360 An analysis will be done to compare the percentage of patients in each treatment group with a  
1361 vision threatening complication. The comparison will be made using a z test. Also, 95%  
1362 confidence intervals will be computed for the percentage in each group and for the difference in  
1363 the percentages. If it is determined that the approximate test is not appropriate, then an exact test  
1364 will be done (Fisher's Exact Test).

1365

### 1366 **5.4.4 Parental Stress**

1367

1368 The Primary Caregiver (defined as the person in the family who provides most of the childcare.)  
1369 will complete both the PSI and the Ocular Treatment Index (OTI) at 3 months after surgery and  
1370 at the first 3-monthly visit after the visual acuity assessment at 12 months of age (i.e., when the  
1371 child is approximately 15 months of age). The purpose for collecting these data is to determine if  
1372 caregivers whose children were assigned to receive a primary IOL report less stress than  
1373 caregivers whose children were randomized to receive the contact lens. Repeated measures  
1374 ANOVA will be used to analyze these data. The specific questions to be investigated are: 1) Are  
1375 the mean PSI and/or OTI scores at 3months after surgery different in the two treatment groups?  
1376 2) Are the mean PSI and/or OTI scores when the child is approximately 15 months of age  
1377 different in the two treatment groups? 3) Within each treatment group are there significant  
1378 changes in parenting stress from 3-months post-surgery to when the child is approximately 15  
1379 months of age? 4) Are the mean changes in parenting stress from 3 months to when the child is  
1380 approximately 15 months of age different in the two treatment groups?

1381

### 1382 **5.4.5 Analyses For Patching Adherence and Other Covariates**

1383

1384 In addition to the analyses on the major outcome variables, other analyses will be done to assess  
1385 the effect of various covariates on the outcomes. These covariate analyses will be viewed with  
1386 caution since the sample size for the study was not determined based on these analyses.

1387 However, relevant information may be identified by these analyses. The most important

1388 covariate of interest is adherence with the patching regimen. We expect that patients who are  
1389 more adherent with the patching regimen will have a more successful visual acuity outcome.

1390 Adherence will be measured three ways: 1) parents will complete a 48-hour recall diary at the 1-  
1391 month follow-up visit and at the 12-month visual assessment visit, 2) parents will keep a one-

1392 week patching diary annually (starting at 2-months post-surgery); 3) an interviewer will call the  
1393 parents four times each year and collect a 48 hour recall of the patching. These data will be used

1394 to construct a measure of adherence. The measure will likely be a weighted average of these  
1395 different sources of information. Measures will be constructed based on different perspectives:

1396 the age of the child, the time point after surgery and a cumulative measure of adherence. The  
1397 adherence measures will not be constructed based upon the association with the outcome.

1398

1399 Within each treatment group the association between adherence and the visual acuity outcome  
1400 will be assessed. The specific technique used for the analysis will depend on the coding scales  
1401 for visual acuity and adherence. The methods likely to be used are chi-square tests, logistic  
1402 regression, analysis of variance and linear regression.

1403  
1404 The level of adherence with the patching regimen will be compared between the two treatments.  
1405 Again, the specific techniques used will depend on the coding for adherence. Chi-square  
1406 techniques will be used if adherence is coded as a categorical variable and analysis of variance  
1407 will be used if adherence is coded as a continuous variable.

1408  
1409 To assess the effect of adherence on the comparison of the treatments, the analyses described  
1410 above for the major outcomes will be done with patients stratified according to an assessment of  
1411 whether they did or did not comply with the patching regimen. Other techniques that will be used  
1412 to compare the two treatment groups adjusting for adherence are analysis of covariance (for the  
1413 outcomes interocular difference in visual acuity and parental stress) and logistic regression (for  
1414 the presence of vision threatening complications). Clearly, the investigation of the effect of  
1415 adherence will be painstaking. In all these analyses, the emphasis will be on estimation rather  
1416 than hypothesis testing.

1417  
1418 Adherence with the optical correction regimen will also be measured. We will examine the same  
1419 questions as described above for adherence with patching. In addition, we will use multivariate  
1420 statistical models such as logistic regression, analysis of variance, and linear regression to  
1421 evaluate the combined effect of adherence with both patching and optical correction regimens.  
1422 Other covariates will be evaluated using similar techniques.

1423

## 1424 **5.5 Interim Monitoring and Analyses**

1425

1426 At six-month intervals, interim study results will be presented to an external Data and Safety  
1427 Monitoring Committee appointed by the National Eye Institute and composed of experienced  
1428 investigators not participating in the study. This committee will evaluate study performance and  
1429 patient safety. We are not proposing the use of interim stopping rules based on the primary  
1430 outcome, visual acuity at 12 months of age, since this assessment will be based on grating acuity  
1431 and we do not think that the study should be stopped for efficacy reasons using grating acuity.  
1432 Optotype acuity is a more definitive visual acuity test but it cannot be performed consistently  
1433 until at least 3.5 years of age. The DSMC will have the responsibility for deciding that the study  
1434 should be stopped early if evidence accumulates that there are serious risks to patient safety.

1435

## 1436 **5.6 Missing Data for the Visual Acuity Assessment**

1437

1438 The problem of a patient having vision below the level that can be measured was discussed in  
1439 Section 4.4.5. In addition, there are several scenarios that could result in missing data and other  
1440 difficulties regarding the visual acuity assessment. The scenarios and the proposed methods for  
1441 handling the problems are as follows:

1442

- 1443 1) Uncooperative Patient Without Evidence for Poor Vision Despite efforts to accomplish a  
1444 visual acuity assessment, including scheduling 3 different testing sessions, it may happen that  
1445 the child is uncooperative to an extent that precludes obtaining a visual acuity assessment  
1446 even though the child can see. The determination that an uncooperative patient can see will  
1447 be based on the observed behavior of the child relative to visual tasks, the qualitative visual  
1448 assessment of the IATS physician, and the parent's description of the child's behavior  
1449 relative to visual tasks  
1450
- 1451 a) If the vision tester, in consultation with Dr. Hartmann (if Dr. Hartmann is not the vision  
1452 tester), concludes that the child has measurable vision in the fellow eye, then for  
1453 statistical analysis an imputed value will be used: the median logMAR value among all  
1454 fellow eyes in the study whose visual acuity could be measured.
- 1455 b) If the vision tester, in consultation with Dr. Hartmann (if Dr. Hartmann is not the vision  
1456 tester), concludes that the child has measurable vision in the aphakic/pseudophakic eye,  
1457 then for statistical analysis, the following imputed value will be used: the logMAR value  
1458 among eyes with the same treatment assignment with a percentile score equal to the  
1459 percentile score of the patient's vision in the fellow eye. The use of this value is an  
1460 attempt to utilize the correlation between a patient's eyes. However, there is the  
1461 assumption that the reason for the child being uncooperative for the treated eye visual  
1462 acuity assessment is unrelated to the vision in that eye. If the fellow eye has poor vision,  
1463 then the median logMAR value among aphakic/pseudophakic eyes with the same  
1464 treatment assignment will be used.  
1465
- 1466 2) Poor Vision in the Fellow Eye For the infant to be eligible for the study, the fellow eye must  
1467 not have any abnormal conditions. However, at the time of the visual acuity assessment, the  
1468 vision may be poor in the fellow eye. One possible reason is that since the baseline  
1469 examination the child has experienced trauma that has affected the vision in the fellow eye.  
1470 Another possible reason is that there is a medical condition affecting the vision in the fellow  
1471 eye that may have been missed at the baseline examination or that developed since the  
1472 baseline examination. The primary outcome is the interocular difference in visual acuity and  
1473 the expectation is that the vision in the fellow eye will be "normal". If the vision in the fellow  
1474 eye is not normal because of trauma or some other condition, a large interocular difference  
1475 favoring the treatment group to which the patient was assigned will result. Although such  
1476 occurrences are expected to be extremely rare and randomization may provide balance  
1477 between the treatment groups, we will also investigate the use of the following imputed value  
1478 for the vision in the fellow eye: the median logMAR value among fellow eyes for which  
1479 visual acuity could be measured. The sensitivity of the analysis comparing treatments to the  
1480 use of the imputed value will be assessed.  
1481
- 1482 3) Patient Not Having Visual Acuity Assessment It may happen that the traveling vision tester  
1483 never examines a particular patient. We expect that this will only happen if the patient is lost  
1484 to follow-up before the visual acuity assessment. An option would be to incorporate the  
1485 information from the qualitative visual acuity assessment done at the 3-monthly visits by the  
1486 physician before the patient was lost. The information from these assessments will be limited  
1487 since the possible values are the 3 ordered categories: No Light Perception, Light Perception,

1488 Fix and Follow. If the patient is lost before any post-operative qualitative visual assessment  
1489 is done the patient will not be included in the analysis. Otherwise, we will investigate using  
1490 imputed values for the missing data as follows:

- 1491
- 1492 a) If the physician has classified the vision in a patient's eye as less than Fix and Follow at  
1493 the last visit before the patient was lost then we will use the imputed logMAR value  
1494 2.6464.
  - 1495 b) If the physician has classified the vision in a patient's eye as Fix and Follow we will  
1496 determine an imputed value according to the methods described in scenario 1) above. We  
1497 will compare the results of the analysis comparing treatments using the imputed values  
1498 for lost patients to the results when lost patients are not included in analysis. A  
1499 disadvantage of using the information from the 3-monthly assessments is the potential for  
1500 bias since the traveling vision tester will not have seen the patient.

1501

1502

1503

## Chapter 6

### Parenting Stress

#### Background:

*Quality of life is an important construct for families and young children. In very young children, limited measures of quality of life that have been validated in a variety of settings and populations are available. However, parenting stress is a key measure of quality of life in families with infants and young children for which well-validated measures are available.*

Parenting stress, defined as stress associated with the parenting role, has been recognized for many years as an important construct in the fields of pediatrics, pediatric psychology, and child development. Low levels of parenting stress during the first 3 years of a child's life are critical to the child's emotional/behavioral development and to the developing parent-child relationship. Excessive parenting stress can lead to dysfunctional parenting, which in turn can lead to behavioral and emotional problems in children. High levels of self-reported parenting stress have been empirically linked with infants' and toddlers' insecure attachment to the mother (Moran & Pederson, 1998; Hadadian & Merbler, 1996), maternal depression (Frankel & Harmon, 1996), and parent-reported behavioral problems (Goldberg et al., 1997).

Parents of infants with congenital conditions, chronic illnesses, and disabilities report greater levels of parenting stress on the Parenting Stress Index (PSI) than control groups (Goldberg et al., 1990; Pelchat et al., 1999; Singer et al., 1999), mainly on the domain assessing perceptions of the child's behavior (Child Domain). Longitudinal studies of parenting stress indicate that stress levels remain high for parents of children with disabilities or chronic illness (Singer et al., 1999; Warfield et al., 1999).

Treatment for unilateral congenital cataract is believed to be stressful for parents because of: (1) the requirement for early surgery, (2) the requirement for early and intensive treatment (including requiring the caregiver to place and maintain a contact lens in the aphakic eye, and patching of the "good" eye), (3) the fact that, even with early treatment, a majority of children with unilateral congenital cataracts develop poor visual acuity in the aphakic eye (Robb et al., 1987; Cheng et al., 1991; Maurer & Lewis, 1993; Lewis et al., 1995), and (4) treatment that may become even more onerous as the child gets older, especially if he/she develops amblyopia. High levels of parenting stress in this population may have negative implications for treatment, as stressed parents may "give up" on patching, contact lens wear or both, settling for suboptimal vision in the aphakic eye.

Proposed changes in treatment for congenital cataracts, such as implantation of an intraocular lens (IOL) at the time of cataract removal, may alleviate some of the parenting stress associated with caring for a child with a unilateral congenital cataract. Given equivalent visual outcomes for the two treatments, the option associated with reduced parenting stress may be preferred by clinicians and parents.



1547 The goal of this aspect of the study is to compare parenting stress after surgery (i.e., three  
1548 months, and again eight-fourteen months after surgery) reported by parents of children receiving  
1549 traditional therapy (aphakic contact lenses) with those randomly assigned to receive a primary  
1550 IOL.

1551

1552 **Administration Plan:**

1553

1554 The Parenting Stress measures will consist of the long version of the Parenting Stress Index and  
1555 a short, condition-specific parenting stress measure, the Ocular Treatment Index. The Parenting  
1556 Stress Index (PSI; Abidin, 1986) is a well-researched, standardized, self-report measure of  
1557 parenting stressors consistently related to dysfunctional parenting. The 120-item scale yields two  
1558 factor-based scores, a Child Domain score and a Parent Domain score, as well as a Total Stress  
1559 score. The Child Domain includes six subscales (Distractibility/Hyperactivity, Adaptability,  
1560 Reinforces Parent, Demandingness, Mood, Acceptability) and the Parent Domain includes seven  
1561 subscales (Competence, Isolation, Attachment, Health, Role Restriction, Depression, Spouse).  
1562 The Life Stress scale assesses situational stress (e.g., death of a relative, loss of a job) outside the  
1563 parent-child relationship. The five response choices for each item range from “strongly agree” to  
1564 “strongly disagree.” For the scale as a whole, the two domains, and the thirteen subscales, higher  
1565 scores indicate greater stress.

1566

1567 The PSI was normed on a sample of 2,633 mothers recruited primarily from a private group  
1568 pediatric practice. Performance on the PSI is interpreted via age-based percentile scores derived  
1569 from the frequency distribution of the normative sample (1 to 12 year olds). All PSI scores have  
1570 well-established internal consistency and test-retest reliability. Factor analyses indicate that each  
1571 subscale measures a moderately distinct source of stress. The construct and concurrent validity of  
1572 PSI scores are supported by significant correlations between Parent Domain subscale scores and  
1573 parental responsiveness (Onufrak, Saylor, Taylor, Eyberg, & Boyce, 1995) and by significant  
1574 correlations between Child Domain scores and parent and teacher ratings of children’s behavior  
1575 problems (Lafiosca & Loyd, 1987). Discriminant validity is supported by the scale’s ability to  
1576 differentiate parents of children with chronic illness, handicaps, or behavior problems from those  
1577 in a control group (e.g., Abidin, 1995; Kazak & Marvin, 1984).

1578

1579 However, disease-specific measures of psychological variables are often preferred to general  
1580 measures because they focus on domains most relevant to the target disease. At the time this  
1581 project was developed, there were no published reports of disease-specific measures of parenting  
1582 stress or quality of life for parents of children with congenital cataract or other ophthalmic  
1583 conditions. As the PSI does not measure parenting stressors specific to the care of a child with  
1584 visual impairments or ocular anomalies, we developed an illness-specific parenting stress  
1585 measure called the Ocular Treatment Index (OTI). The OTI consists of 28 Likert-type items  
1586 with five response choices ranging from “strongly agree” to “strongly disagree”. All items were  
1587 written by an interdisciplinary research team (pediatric ophthalmologist, epidemiologist, clinical  
1588 child psychologist, and orthoptist) based upon clinical experience with cataract patients, a focus  
1589 group with parents of children with UCC, and familiarity with the child development and  
1590 pediatric psychology literatures. Preliminary validation of this measure has been published and  
1591 a slightly modified version of the measure has been used in the Amblyopia Treatment Study.

1592

1593 After review of the proposed scales, a few items were added by the IATS Advisory Committee  
1594 and the parents of two young children with bilateral congenital cataracts. In pilot studies,  
1595 internal consistency between the 28 items on the scale had an observed Cronbach's alpha of  
1596 0.94. The observed range on the scale was 47 to 123 versus a theoretical range of 28-140. The  
1597 mean total score was 85.2, with a standard deviation of 20. This suggests a good distribution of  
1598 scores. Further, as predicted a priori, the OTI was positively correlated with 11 of 13 PSI  
1599 subscales, but was not associated with either age or the Life Stress subscale of the PSI.

1600

1601 We will administer the Parenting Stress Index and the OTI to parents at 3 months after surgery  
1602 and at the first 3-monthly visit following the visual acuity assessment. These two questionnaires  
1603 will be administered as a single "caregiver questionnaire" in English or Spanish depending on  
1604 the language preference of the primary caregiver. The caregiver questionnaire will be given to  
1605 the primary caregiver to be completed at the office visit. Upon completion of the caregiver  
1606 questionnaire, the caregiver will seal the questionnaire in an envelope for the clinic coordinator  
1607 to mail to the DCC.

1608

#### 1609 **Analysis:**

1610

1611 Power considerations and the statistical analysis of the parenting stress outcome are presented in  
1612 Chapter 5 Statistical Considerations.

1613

#### 1614 **Procedure for Handling Elevated Parenting Stress Index (PSI) Scores:**

1615

1616 DCC staff will score the PSI within one week of receipt. If a participant's Total Stress raw score  
1617 is at or above 260 (> 85<sup>th</sup> percentile for 1 year olds), DCC data entry staff will alert the IATS  
1618 psychologist within 24 hours. The psychologist will examine the participant's PSI profile within  
1619 48 hours to determine whether the participant should be contacted by phone to discuss a referral  
1620 for mental health services. The cut-off score of 260 is recommended by the developers of the PSI  
1621 (Abidin, 1995). Reports to the DSMC every six months will include the number of participants  
1622 with a score > 260, the number that are called by the psychologist, and the outcome of those  
1623 calls.

1624

1625 The decision to contact a participant due to an elevated PSI Total Stress score is complex and  
1626 involves clinical judgment as well as an understanding of scale psychometric properties.

1627

1628 Examples include:

1629

1630 - The elevated PSI Total Stress score may reflect an elevated Child Domain score, with Parent  
1631 Domain and Life Stress scores in the normal range. In this case, it is likely that child  
1632 characteristics, rather than parent characteristics, are primarily contributing to the stress in the  
1633 parent-child system. A referral for mental health services for the parent may not be needed.

1634

- 1635 - If the elevated PSI Total Stress score is accompanied by a Life Stress raw score above 17, the  
1636 parent is experiencing a considerable degree of stress both within and outside the parent-child  
1637 relationship, and a referral for mental health services may be warranted.  
1638
- 1639 - If the elevated PSI Total Stress score includes an elevated Health or Depression subscale score,  
1640 the parent may be experiencing significant clinical depression or health problems. The parent  
1641 may be advised to talk with his or her health care provider, and/or a referral to mental health  
1642 services may be given.  
1643

#### 1644 **References for Parenting Stress**

- 1645 Abidin, R.R. (1995). Parenting Stress Index: Professional Manual (3<sup>rd</sup> Ed.). Odessa, FL:  
1646 Psychological Assessment Resources, Inc.  
1647
- 1648 Frankel, K.A., & Harmon, R.J. (1996). Depressed mothers: They don't always look as bad as  
1649 they feel. Journal of the American Academy of Child & Adolescent Psychiatry, 35, 289-298.  
1650
- 1651 Goldberg, S., Janus, M., Washington, J., Simmons, R.J., MacLusky, I., & Fowler, R.S.  
1652 (1997). Prediction of preschool behavioral problems in healthy and pediatric samples. Journal of  
1653 Developmental & Behavioral Pediatrics, 18, 304-313.  
1654
- 1655 Goldberg, S., Morris, P. Simmons, R.J., Fowler R.S., et al. (1990). Chronic illness in infancy  
1656 and parenting stress: A comparison of three groups of parents. Journal of Pediatric Psychology,  
1657 15, 347-358.  
1658
- 1659 Hadadian, A., & Merbler, J. (1996). Mother's stress: Implications for attachment  
1660 relationships. Early Child Development & Care, 125, 59-66.  
1661
- 1662 Hauenstein, E.J., Marvin, R.S., Snyder, A.L., & Clarke, W.L. (1989). Stress in parents of  
1663 children with diabetes-mellitus. Diabetes Care, 12, 18-23.  
1664
- 1665 Innocenti, M.S., Huh, D., & Boyce, G.C. (1992). Families of children with disabilities:  
1666 Normative data and other considerations on parenting distress. Topics in Early Childhood  
1667 Special Education, 12, 403-427.  
1668
- 1669 Kazak, A.E., & Marvin, R.S. (1984). Differences, difficulties and adaptation: Stress and  
1670 social networks in families with a handicapped child. Family Relations, 33, 1-11.  
1671
- 1672 Lafiosca, T., & Loyd, B. (1986). Defensiveness and the assessment of parental stress and  
1673 anxiety. Journal of Clinical Child Psychology, 15, 254-259.  
1674
- 1675 La Greca, A.M., & Lemanek, K.L. (1996). Editorial: Assessment as a process in pediatric  
1676 psychology. Journal of Pediatric Psychology, 21, 137-151.  
1677

- 1678 Moran, G., & Pederson, D.R. (1998). Proneness to distress and ambivalent relationships.  
1679 Infant Behavior & Development, *21*, 493-503.
- 1680
- 1681 Onufrak, B., Saylor, C.F., Taylor, M.J., Eyberg, S.M., & Boyce, G.C. (1995). Determinants of  
1682 responsiveness in mothers of children with intraventricular hemorrhage. Journal of Pediatric  
1683 Psychology, *20*, 587-599.
- 1684
- 1685 Pelchat, D., Ricard, N., Bouchard, J-M, Perreault, M., Saucier, J-F, Berthiaume, M., &  
1686 Bisson, J. (1999). Adaptation of parents in relation to their 6-month-old infant's type of  
1687 disability. Child: Care, Health & Development, *25*, 377-397.
- 1688 Robson, A.L. (1997). Low birth weight and parenting stress during early childhood. Journal of  
1689 Pediatric Psychology, *22*, 297-311.
- 1690
- 1691 Singer, L.T., Salvator, A., Guo, S., Collin, M., Lilien, L., & Baley, J. (1999). Maternal  
1692 psychological distress and parenting stress after the birth of a very low-birth-weight infant.  
1693 JAMA, *281*, 799-805.
- 1694
- 1695 Smith, K.H., Baker, D.B., Keech, R.V. et al (1991). Monocular congenital cataracts:  
1696 Psychological effects of treatment. Journal of Pediatric Ophthalmology and Strabismus, *28*, 245-  
1697 249.
- 1698
- 1699 Smith, L.K., Thompson, J.R., Woodruff, G., & Hiscox, F. (1995). Factors affecting treatment  
1700 compliance in amblyopia. Journal of Pediatric Ophthalmology and Strabismus, *32*, 98-101.
- 1701
- 1702 Warfield, M.E., Krauss, M.W., Hauser-Cram, P., Upshur, C.C., & Shonkoff, J.P. (1999).  
1703 Adaptation during early childhood among mothers of children with disabilities. Journal of  
1704 Developmental and Behavioral Pediatrics, *20*, 9-16.
- 1705

**Table 1****Items on the Revised Ocular Treatment Index (OTI)**

---

1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750

1. My child's poor vision gets in the way of his/her learning.
2. I am afraid that my child will never have good vision.
3. I don't like the way my child's treated eye looks.
4. Taking my child to the eye doctor is stressful.
5. I have trouble putting on my child's patch.
6. The patch irritates my child's skin.
7. I worry that my child will become injured when the patch is on.
8. I worry that my child will take his/her patch off when I am not around.
9. Patching is a source of tension or conflict in my marriage.
10. My child is much less active when patched than when not patched.
11. I worry that my child will be teased when he/she is wearing an eye patch.
12. My child can see well with his/her patch on.<sup>a</sup>
13. I have trouble keeping the patch on my child.
14. My child is clumsy and uncoordinated when patched.
15. I worry about what others may think when they see my child with his/her patch on.
16. I have trouble getting my child to wear the patch.
17. Patching is a source of tension or conflict in my relationship with my child.
18. I worry that my child does not wear the patch enough.
19. I worry that my child's contact lenses or glasses will become broken.
20. I worry that my child will be injured because of wearing his/her contact lenses or glasses.
21. Wearing glasses or contact lenses is comfortable for my child.<sup>a</sup>

- 1751 22. Replacing my child's glasses or contact lenses is expensive.  
1752  
1753 23. I worry that my child's contacts will fall out or glasses will fall off during the day.  
1754  
1755 24. My child's eye becomes pink or bloodshot from wearing his/her contact lenses or glasses.  
1756  
1757 25. I can't leave my child with other people because I am afraid that he/she will lose his/her  
1758 contacts or glasses.  
1759  
1760 26. I am worried that my child's glasses or contact lenses will become scratched.  
1761
- 

1762  
1763 Note. <sup>a</sup> Item is reversed in scoring.

1764

**Table 2**

**Correlations of Parenting Stress Index (PSI) Scores  
with the Ocular Treatment Index (OTI)**

---

1768		
1769	PSI Child Domain summary score	.46 <sup>b</sup>
1770		
1771	Distractibility subscale	.23
1772	Adaptibility subscale	.38 <sup>c</sup>
1773	Reinforces Parent subscale	.44 <sup>b</sup>
1774	Demandingness subscale	.54 <sup>a</sup>
1775	Mood subscale	.42 <sup>b</sup>
1776	Acceptibility subscale	.38 <sup>c</sup>
1777		
1778	PSI Parent Domain summary score	.59 <sup>a</sup>
1779		
1780	Competence subscale	.53 <sup>a</sup>
1781	Isolation subscale	.41 <sup>b</sup>
1782	Attachment subscale	.07
1783	Health subscale	.36 <sup>c</sup>
1784	Role Restriction subscale	.74 <sup>a</sup>
1785	Depression subscale	.38 <sup>c</sup>
1786	Spouse subscale	.55 <sup>a</sup>
1787		
1788	PSI Total Score	.55 <sup>a</sup>

---

Note. <sup>a</sup> $p < .01$ , <sup>b</sup> $p < .05$ , <sup>c</sup> $p < .10$ .

1789

1790

1791

1792

1793

1794

## Chapter 7

### Adherence

#### 7.1 General Principles

Parental adherence to the treatment regimen of patching and visual correction with contact lenses or spectacles is believed to play an important role in the visual outcome of children with unilateral congenital cataracts (UCC) (Birch & Stager, 1988). In fact, it is possible that any improved visual acuity among children with a UCC who receive a primary IOL may be enhanced by improved adherence to the treatment regimen. Assessing use of the patch, contact lens and spectacles will be important to determine if:

- Improved visual outcome is associated with better adherence to the treatment regimen among children receiving a single type of treatment (i.e., among aphakic children or among pseudophakic children),
- Adherence is better in pseudophakic than aphakic children, or vice versa, and
- Adherence to the treatment protocol contributes to a better visual outcome among pseudophakic children than aphakic children, or vice versa.

We will use parental reports to assess adherence to the patching regimen and use of contact lenses and/or spectacles. Neither automated adherence tools nor standardized questionnaires to assess adherence to patching and visual correction among preschool-aged children are available. Further, limited data exist on the most valid type of parental questionnaire to assess adherence to a medical regimen among preschool-aged children. Most assessments of adherence to medical regimens use pill counts, which cannot be applied to assessment of patching or visual correction. “Smart Patches” to assess adherence with patching regimens are under development. However, at this point they are neither acceptable to parents nor able to assess adherence with both patching and visual correction.

Therefore, we modeled our assessment of adherence after dietary assessments, which have been used in a variety of epidemiologic studies, including those of dietary assessment of preschool-aged children. Many studies of diet have used a combination of a series of 24-hour dietary recalls and 3- to 7-day weighed dietary records.

Two types of parental report of adherence to recommended patching and visual correction will be obtained in this study: 1) an eye-care diary and 2) a quarterly 48-hour recall interview.

#### 7.2 Results of Pilot Study of Adherence Measures

In our randomized pilot study we obtained both interview and diary data on 11 of 17 subjects. Interview and diary information provided similar data on patching compliance (i.e., within 5%) for 3 of the 11 subjects for whom both data sources were available. Another two subjects



1840 provided similar information if the fact that, based on the diary, they were patching all day, every  
1841 other day was taken into account. The two sources estimated a different amount of patching for  
1842 the remaining six. For two subjects, the amount of patching was higher when reported on the  
1843 interview, and for four subjects, the amount of reported patching was higher on the diary. These  
1844 differences may reflect the fact that these data were collected over different time periods and/or  
1845 different degrees of accuracy. We believe that this information justifies our proposal to assess  
1846 compliance using both interviews and diaries.

1847  
1848 First, it was possible to interview most of the caregivers, usually with little difficulty. Secondly,  
1849 we were able to contact women and provide them with a connection to the study and study staff.  
1850 In one case, this resulted in the child getting needed visual correction. Finally, it appears that  
1851 some women have an easier time reporting information on an interview when they are being  
1852 cued than on a diary. For example, one woman obviously failed to document daytime naps on  
1853 her diary that she did report on the interview. On the other hand, some women were unable to  
1854 report on treatment during certain hours of the day because another caregiver was caring for the  
1855 child. These women were able to get this information from the caregiver on the diary. Further,  
1856 we were able to use these methods to assess not only compliance with patching, but also  
1857 patching with visual correction. Such assessment would not be possible with some other  
1858 automated types of compliance assessment.

### 1859 1860 **7.3 Eye-Care Diary**

1861  
1862 Two types of eye-care diaries will be kept:

1863  
1864 48-Hour Eye-Care Diary - At the one month visit, the parent and/or primary caregiver will  
1865 complete an eye-care diary to report patching and visual correction over the previous 48-hours.  
1866 At this visit, the clinic coordinator will provide training in how to complete this diary. The  
1867 coordinator and the caregiver will review an example scenario and together they will complete a  
1868 diary based on this scenario. The caregiver will then be provided the opportunity to ask  
1869 questions on completing the diary. The caregiver will then complete a diary reporting patching,  
1870 sleeping and visual correction for the previous 48-hours. The diary at the one-month visit will be  
1871 used, in part, to train the Parents/Caregivers on how to complete the diary. After the caregiver  
1872 completes the 48-hour diary, the diary will be placed in a sealed envelope and mailed to the DCC  
1873 by the Clinical Coordinator.

1874  
1875 7-Day Eye-Care Diary – A 7-Day Eye Care Diary will be mailed 1-month after both the 1-month  
1876 visit and the visual acuity assessment visit. This diary will be completed, prospectively by all  
1877 caregivers over the 7-days starting the following Sunday. 7-Day Eye Care Diaries will then be  
1878 completed annually when the child is 25, 37 and 49 months of age. The 7-Day Eye Care Diaries  
1879 will prospectively document wake times, patching and visual correction use over a one-week  
1880 period starting Sunday morning. The diaries will be mailed from the DCC to the primary  
1881 caregiver, along with instructions. After completion, the caregiver will mail the 7-Day Eye Care  
1882 Diary directly back to the DCC.

1883

1884 **7.3.1 Administration of Eye-Care Diary**

1885

1886 48-Hour Eye-Care Diary

1887

1888 At the 1-month visit, the Clinic Coordinator will go over an example day with the parent, and  
1889 together they will complete an example eye-care diary before the caregiver completes the 48-  
1890 hour eye-care diary. This will provide the parent or caregiver with training on how to complete  
1891 the eye-care diary. The parent should be allowed to ask questions while he/she is working with  
1892 the coordinator to complete the example diary. The parent/caregiver will also be able to take this  
1893 “example” diary and scenario home to refer to when completing the 7-day eye-care diary. The  
1894 Clinic Coordinator should record comments about the training session and completion of the  
1895 eye-care diary in the comments section, and mail the 48-hour Eye-Care diary to the DCC as soon  
1896 as possible after the visit.

1897

1898 At the 1-month visit the Clinic Coordinator should remind the caregiver that:

1899

1900 - The DCC will be sending 7-day eye-care diary to the parent approximately in  
1901 approximately 1 month. The diary should be prospectively completed throughout the  
1902 week starting Sunday morning, rather than completed at the end of the week.

1903

1904 - A quarterly 48-hour recall interview of patching, visual correction and sleeping will be  
1905 completed over the telephone.

1906

1907 7-Day Eye-Care Diary

1908

1909 The 7-Day eye-care diary is intended to be completed prospectively every year. This should  
1910 minimize errors related to changing care-givers and retrospectively recalled data.

1911

1912 The eye-care diary will be mailed from the DCC. Each Thursday the DCC will generate a list of  
1913 all subjects whose 1-month visit or Visual Acuity Assessment Visit was 4 weeks prior. The  
1914 DCC will also generate lists of participants who are turning 25, 37, or 49 months of age. The  
1915 DCC will then mail the 7-Day Eye Care Diary the following Monday. On the selected day of the  
1916 month, the diaries will be mailed to the respondent’s home address. The mailing will include:  
1917 The eye-care diary, a self-addressed stamped, envelope and a cover letter.

1918

1919 The caregiver will have received instruction on how to complete the eye-care diary at the 1  
1920 month follow-up visit. The cover letter sent with the diary will re-introduce the eye-care diary,  
1921 and explain that the parent is to start recording patching and visual correction information for 7  
1922 complete days, starting Sunday morning. The DCC will contact the caregiver on Saturday to  
1923 make sure they had received the diary and to remind them to start keeping the diary the next  
1924 morning. Over, the subsequent week, the primary caregiver and all other caregivers are to record  
1925 all wake, sleep, patch on, patch off, contact lens on, contact lens off, spectacles, and spectacles  
1926 off times starting when the child wakes the next morning.

1927

1928 When the diary is completed, the parent is to return the diary, by mail, in a self-addressed,  
1929 stamped envelope provided with the diary. Upon receipt, the DCC Staff will record that the  
1930 diary has been returned and review the form for completeness. The DCC will contact the parent  
1931 about any missing or illegible information and then fax the completed form into the DCC  
1932 computer for entry into the database.  
1933

1934 Two weeks after the date that the diaries were mailed, the DCC staff will identify all diaries that  
1935 have not yet been returned. The DCC will contact parents by telephone to remind them to  
1936 complete the diary and return it, whenever a diary is not returned within 14 days.  
1937

#### 1938 **7.4 48-Hour Adherence Interview**

1939  
1940 Staff at the DCC will conduct a telephone interview of patching adherence and use of visual  
1941 correction approximately every 3 months, starting 3 months after surgery. The adherence  
1942 interview is a 30-minute, structured telephone interview designed to gain information about the  
1943 proportion of time while awake that the child wore the patch and visual correction during the  
1944 previous 48-hours. Because patching can be prescribed for 50% of waking hours every day or all  
1945 day every other day, it is important that this interview be a true "48-hour" recall rather than the  
1946 previous day. The structure of the interview uses questions about the child's activities, sleep and  
1947 wake times, meal times, bath times, etc. as anchors to improve recall. For example, research has  
1948 shown that memory can be improved by asking the caregiver to recall what time the child woke,  
1949 when he/she was dressed, and when he/she had breakfast, and then asking if the child was  
1950 wearing his/her patch, contact lens, glasses, at these times.  
1951

1952 At the end of each month, the DCC will generate two lists of subjects: 1) all subjects whose  
1953 enrollment date was 3, 9, 15, 21, 27, 33, 39, or 45 months previous, and 2) all subjects whose  
1954 enrollment date was 6, 12, 18, 24, 30, 36, 42, or 48 months previous.  
1955

1956 For each of these two lists, the DCC will then randomly generate a number from 1 to 31 (28 for  
1957 February, 30 for April, June, September and November) indicating which day of the month (i.e.,  
1958 the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, or 4<sup>th</sup>) the interviews will be conducted. The DCC will start conducting the  
1959 adherence interviews for each group of participants on these selected days. If the date selected  
1960 for the interview overlaps the dates that the 7-Day Eye Care Diary is being kept the target date  
1961 for the interview will be adjusted by one week (i.e., Date + 7).  
1962

1963 If the DCC is unable to complete an interview on the day for that participant, they will attempt to  
1964 conduct the interview the next day for four consecutive days. However, in order to obtain as  
1965 much information about both weekend and week days as possible, if the selected day is a  
1966 weekend day (i.e., Saturday or Sunday), the interviews will be attempted on four consecutive  
1967 weekend days. If the selected day is a weekday, the interviews will be attempted on four  
1968 consecutive weekdays. If the interview is not completed after the four attempts the DCC will  
1969 make two additional attempts to conduct the interview over the next week, regardless of the day  
1970 of the week. If the interview has still not been completed after this time, the participant will be  
1971 considered a potential lost to follow-up, and the DCC will contact the clinical center in an

1972 attempt to locate the participant. All contact with a patient's family will be recorded on a Contact  
1973 Log Form.  
1974  
1975

## Chapter 8

### Certification of Personnel

1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020

#### 8.1 Certification of Surgeons

The certification process for an IATS surgeon will include:

1. Completion of a pediatric ophthalmology fellowship.
2. Experience performing cataract surgery including the placement of IOLs in children.
3. Availability of an anesthesiologist experienced in managing infants.
4. Approval by the NEI of the surgeon's clinical center as an IATS center.
5. Passing a certification examination that will be prepared by the study chair. The examination will be placed on a secure website by the Jaeb Center and administered online. The Jaeb Center will maintain the website and grade the examinations. The certification examination will ensure that the surgeon is familiar with IATS protocol.
6. Submission of a videotape to Ed Wilson, MD, of the surgeon performing cataract surgery with IOL implantation on a child less than two years of age. The surgeon should follow the IATS surgical protocol during the procedure.

After the completion of the steps above, the surgeon will be given a 3-digit certification number by the DCC. The surgeon will then be eligible to enroll patients in IATS.

#### *Recertification of Surgeons*

*Surgeons will be required to provide a video of every IATS enrollment surgery as a means of monitoring adherence to the surgical protocol. At least one video per year must be of an IATS protocol IOL implantation. If an IOL has not been implanted in an enrolled patient in the previous year, the surgeon must provide a video of a protocol IOL implantation in a young child in order to maintain certification.*

#### 8.2 Certification of Clinical Coordinators

The certification process for an IATS clinical coordinator will include:

1. Reading the IATS Manual of Procedures and Protocol.
2. Passing the IATS certification examination online. The certification examination will be the same one taken by the IATS surgeons and will be maintained on a secure website by the Jaeb Center.

#### 8.3 Certification of Traveling Examiners

The traveling examiners who will evaluate ocular motility and visual acuity (at Age 12 months) will be trained and certified by E. Eugenie Hartmann, PhD.

The certification process for the traveling examiners will include:

1. A 3-month training period including:
  - A. Study of the Teller Acuity Card manual
  - B. Supervised practice in testing normal infants and children

- 2021 C. Supervised practice in testing pediatric patients with a history of cataracts,  
2022 strabismus, and/or nystagmus  
2023
- 2024 2. Passing a certification examination that will include:  
2025 A. Evaluation of inter-observer test/retest reliability for Teller Acuity Cards between the  
2026 traveling examiner and experienced laboratory personnel  
2027 B. Passing a certification examination prepared by E. Hartmann, PhD, to ensure  
2028 familiarity with all details of the acuity testing procedures and the IATS acuity  
2029 protocol  
2030
- 2031 3. On-going reliability checks will be obtained between E. Eugenie Hartmann, PhD and the  
2032 traveling examiner at the Visual Testing Center. These assessments will be conducted at regular  
2033 intervals, either in terms of time or number of acuity assessments completed by the traveling  
2034 examiner, whichever is deemed more appropriate during the course of the study to maintain  
2035 quality control of the acuity testing. Specifically, the traveling examiner and Dr. Hartmann will  
2036 conduct at least one reliability session every two months or for every 6 infants tested for the  
2037 study.  
2038

#### 2039 **8.4 Certification of Contact Lens Professionals**

2040 The certification process for a contact lens *professional* to fit infants enrolled in IATS will  
2041 include:

- 2042 1. Reading the IATS Manual of Procedures and Protocol  
2043 2. Passing the IATS contact lens certification examination online. The certification examination  
2044 will be prepared by the study headquarters and placed online by the Jaeb Center at a secure  
2045 website. The Center will communicate by e-mail whenever a contact lens *professional* has  
2046 passed the examination and is therefore certified.